



PAKISTAN  
CHEST SOCIETY  
STRIVING FOR PULMONARY CARE

Clinical Practice  
Guidelines

# Community Acquired Bacterial Pneumonia

PAKISTAN CHEST SOCIETY-2026



# Community Acquired Bacterial Pneumonia

## **Pakistan Chest Society**

Prepared by the Pakistan Chest Society for National Guidance on the  
Diagnosis and Management of Community Acquired Bacterial Pneumonia

---

March 2026



PAKISTAN  
CHEST SOCIETY  
STRIVING FOR PULMONARY CARE



# Table of Contents

Preface	01
Message by the President, Pakistan Chest Society	02
Message by the Chairman, Guideline committee, Pakistan Chest Society	03
Pakistan Chest Society Guideline Committee	04
Community-Acquired Bacterial Pneumonia Guideline Working Group	05
Acknowledgement from the Chair, Committee for Community Acquired Pneumonia guidelines development	06
<b>Chapter 01</b>	<b>07</b>
Introduction	
<b>Chapter 02</b>	
<b>Epidemiology and Etiology of CAP in Pakistan</b>	
National Burden and Incidence	09
Factors associated with a higher mortality included	09
Microbial Etiology in Adults	10
Viral Co-Infections and Emerging Respiratory Pathogens	10
Geographic Variability and Data Gaps	10
Risk Factors for CAP in Pakistan	10
<b>Chapter 03</b>	<b>11</b>
<b>Antimicrobial Resistance (AMR) Trends and Empiric Treatment Challenges in CAP – Pakistan Context</b>	
AMR in <i>Streptococcus pneumoniae</i>	11
AMR in <i>Haemophilus influenzae</i>	11
Gram-Negative Resistance – <i>K. pneumoniae</i> and <i>P. aeruginosa</i>	11
Inappropriate Empiric Therapy and Its Consequences	11

# Table of Contents

---

## **Chapter 04** **12**

### **Risk Stratification and Severity Assessment in CAP**

CURB-65 and CRB-65: The Most Common Tools in Pakistan .....	<b>12</b>
PSI (Pneumonia Severity Index) .....	<b>12</b>
SMART-COP and SCAP Scores .....	<b>13</b>
Limitations and Local Adjustments .....	<b>13</b>

---

## **Chapter 05** **14**

### **Evaluation and Diagnostic Work up in CAP**

Clinical Evaluation .....	<b>14</b>
Radiological Assessment .....	<b>14</b>
Microbiological Testing .....	<b>15</b>
Biomarkers .....	<b>15</b>
COVID-19 and Respiratory Viral Co-infections .....	<b>16</b>
Diagnostic Gaps in Pakistan .....	<b>16</b>
PCS Recommendations to Address Gaps .....	<b>16</b>

---

## **Chapter 06** **17**

### **Empirical Antibiotic Therapy and Treatment Algorithm for CAP in Pakistan**

Principles of Empirical Therapy in CAP .....	<b>17</b>
Risk Factors for Drug-Resistant Pathogens (DRPs) .....	<b>17</b>
Pakistani Empirical Treatment Algorithm (Adult CAP) .....	<b>17</b>
Duration of Therapy .....	<b>18</b>
Role of Antimicrobial Stewardship .....	<b>18</b>
Pakistan-Specific Algorithm .....	<b>18</b>
Table 6.1 – Empirical Antibiotic Algorithm (CAP – Adults, Pakistan) .....	<b>18</b>

---

## **Chapter 07** **19**

### **Microbiological Confirmation and Antimicrobial Stewardship Strategy**

Gaps in Pakistan's Microbiology Practices .....	<b>19</b>
Role of Antimicrobial Stewardship (AMS) .....	<b>19</b>
Regional Models of AMS and Microbiology Integration .....	<b>19</b>
Future Directions for Pakistan .....	<b>20</b>

# Table of Contents

---

## **Chapter 08** **21**

### **Follow-Up, Monitoring, and Patient Outcomes**

Early Reassessment .....	21
Imaging During Hospitalization .....	21
Criteria for IV-to-Oral Switch and Discharge .....	21
Radiological Follow-Up Post-Recovery .....	22
Outcomes and Mortality Trends .....	22
Post-Discharge Planning and Readmission Prevention .....	22
Recommendations .....	22

---

## **Chapter 09** **23**

### **Special Populations in CAP Management**

Elderly Patients .....	23
Immunocompromised Patients .....	23
Pregnant Women .....	24
National and International Recommendations for High-Risk Groups .....	24
Urgent Needs in Pakistan .....	24

---

## **Chapter 10** **25**

### **Prevention Practices**

Pneumococcal Vaccination .....	25
Influenza Vaccination .....	25
Risk Factor Modification .....	26
Structured Screening and Education .....	26
National Policy Recommendations for Pakistan .....	26

---

## **Chapter 11** **27**

### **Implementation of Framework and National Roll-Out Strategy**

Governance and Policy Alignment .....	27
Tiered Roll-Out Strategy .....	28
Capacity Building and Digital Training .....	28
Monitoring and Evaluation .....	28
Financing and Procurement .....	28
Community Engagement and Literacy .....	28
Global Lessons and Local Adaptation .....	28
Summary and Way Forward .....	28

# Table of Contents

---

## **Chapter 12** **29**

### **Research Priorities and Future Directions**

Epidemiological Surveillance .....	<b>29</b>
Microbiological and Resistance Mapping .....	<b>29</b>
Diagnostic Algorithms and Biomarker Utility .....	<b>29</b>
Outcome Studies and Therapeutic Trials .....	<b>30</b>
Implementation Science and Behavioral Research .....	<b>30</b>
Regional Collaboration and Data Sharing .....	<b>30</b>
Research Coordination and Funding .....	<b>31</b>
Conclusion .....	<b>31</b>

---

## **Chapter 13** **32**

### **Summary of Key Recommendations and Algorithmic Pathways**

Summary of Core Clinical Recommendations .....	<b>32</b>
Definition .....	<b>32</b>
Common Pathogens .....	<b>32</b>
Severity Assessment .....	<b>32</b>
Diagnostic Recommendations .....	<b>32</b>
Empirical Antibiotic Therapy (Based on Resistance Trends and Risk Factors) .....	<b>32</b>
Oral Switch & Duration .....	<b>32</b>
Vaccination Recommendations .....	<b>32</b>
Clinical Algorithm .....	<b>33</b>
Health System Implementation Priorities .....	<b>34</b>
PICO Questions .....	<b>34</b>
References .....	<b>41</b>

# Preface

---

Community-acquired bacterial pneumonia (CABP) remains a leading cause of morbidity and mortality in Pakistan, exerting a disproportionate burden on vulnerable populations while simultaneously straining an already resource-constrained healthcare system. The evolving epidemiology of respiratory pathogens, the accelerating threat of antimicrobial resistance, and the expanding armamentarium of diagnostics and therapeutics demand a timely, context-sensitive reappraisal of clinical practice.

These updated guidelines represent a deliberate effort to bridge global evidence with local realities. While informed by contemporary international data and best practices, they are firmly grounded in the epidemiological patterns, healthcare infrastructure, and socioeconomic constraints unique to Pakistan. Particular emphasis has been placed on pragmatic decision-making—balancing diagnostic precision with feasibility, and therapeutic efficacy with affordability and accessibility.

A key strength of this document lies in its multidimensional approach. Beyond antimicrobial selection, it integrates risk stratification, severity assessment, stewardship principles, and systems-level considerations, including referral pathways and levels of care. Importantly, it acknowledges the heterogeneity of care delivery across urban tertiary centers and rural primary facilities, offering adaptable recommendations that retain clinical rigor without sacrificing practicality.

The guidelines also recognize that optimal CABP management extends beyond pharmacotherapy. Early identification, rational use of diagnostics, prevention strategies, and patient-centered care are equally critical pillars. In an era where overuse of broad-spectrum antibiotics threatens future therapeutic viability, these recommendations underscore the ethical and clinical imperative of judicious prescribing.

This document is intended not merely as a reference, but as a catalyst—for standardizing care, reducing unwarranted variation, and ultimately improving patient outcomes nationwide. Its success, however, will depend on collective ownership by clinicians, policymakers, and institutions alike.

In confronting CABP, the challenge is not a lack of knowledge, but the disciplined application of it—consistently, equitably, and wisely.

## Message by the President Pakistan Chest Society

---

Community-acquired pneumonia continues to contribute significantly to morbidity and mortality across all age groups. These guidelines emphasize early risk stratification, judicious antibiotic use, and evidence-based supportive care. By aligning global standards with local microbial patterns and resistance trends, PCS aims to enhance clinical decision-making and antimicrobial stewardship.



### **Prof. Shereen Khan**

---

President  
Pakistan Chest Society

## Message by the Chairman

### Guideline Committee, Pakistan Chest Society

---

It gives me great pleasure to present the **Guidelines for the Management of Community Acquired Pneumonia (CAP)** by the Pakistan Chest Society. These guidelines are a key step toward improving and standardizing the care of pneumonia patients across Pakistan, where respiratory infections remain common and often life-threatening if not treated early.



Community Acquired Pneumonia is an infection of the lungs that develops outside hospital settings. In Pakistan, factors such as overcrowding, malnutrition, air pollution, smoking, repeated infections, and late medical consultation increase the incidence and severity of pneumonia. Recognizing these local factors is essential for proper diagnosis and treatment.

The CAP Working Group, under the leadership of Prof. Muhammad Zill-e-Humayun Mirza, has adapted international evidence to suit Pakistan's healthcare environment. The guidelines outline important causes, clinical evaluation, and appropriate management strategies tailored to our population.

Early diagnosis is crucial. A thorough history, physical examination, chest X-ray, pulse oximetry, and basic blood tests are recommended for initial assessment. Severity scores like CURB-65 help determine whether treatment should be at home, in the ward, or in ICU. Additional tests such as sputum culture or blood culture may be used when needed.

Management must be prompt and evidence-based. Early initiation of suitable antibiotics, along with supportive measures including oxygen if required, hydration, fever control, respiratory physiotherapy, and vaccination are strongly emphasized. Avoiding smoke and pollutants and seeking care early can significantly improve outcomes.

These guidelines aim to reduce complications, hospital stays, and mortality, while ensuring that patients receive timely and effective treatment. We thank all members involved in preparing these recommendations and remain committed to advancing respiratory health and evidence-based medical practice across Pakistan.

## **Prof. Muhammad Ashraf Jamal**

Chairman Guideline Committee  
Pakistan Chest Society

# Pakistan Chest Society

## Guideline Committee

---

### **Prof. Muhammad Ashraf Jamal**

Chairman, Guidelines Committee  
Pakistan Chest Society

### **Prof. Nisar Ahmed Rao**

Professor of Pulmonology  
Fazaia Ruth Pfau Medical College Hospital, Karachi

### **Prof. Saadia Ashraf**

Head of the Pulmonology Department  
Khyber Teaching Hospital, MTI, Peshawar

### **Brig (R) Jamal Ahmad**

Head of the Pulmonology Department  
Fauji Foundation Hospital Rawalpindi

### **Prof. Talha Mahmood**

Professor Head of Department (Pulmonology)  
Shaikh Zayed Medical Complex, Lahore

### **Dr. Maqbool A Langove**

Associate Professor, Department of Pulmonology  
Fatima Jinnah General and Chest Hospital, Quetta

### **Dr. Kamran Khan Sumalani**

Associate Professor, Department of Pulmonology  
Jinnah Postgraduate Medical Center, Karachi

# Community-Acquired Bacterial Pneumonia Guideline Working Group

---

## **Prof. Muhammad Zill-e-Humayun Mirza**

Chair, CAP Guideline development Committee  
Pakistan Chest Society

## **Prof. Masood ul Haq**

Assistant Professor & Head of Department  
Sheikh Zayed Medical College, Rahim Yar Khan

## **Prof. Muhammad Irfan**

MBBS, FCPS (Medicine and Pulmonology)  
Aga Khan University Hospital, Karachi

## **Brig (R) Prof. Muhammad Imran**

Consultant Pulmonologist  
Kulsum International Hospital, Islamabad

## **Prof. Irfan Malik**

Associate Professor, Department of Pulmonology  
Lahore General Hospital, Lahore

## **Dr. Madiha Siddiqui**

Clinical Manager  
Indus Hospital, Karachi

## **Dr. Rizwan Athar**

Head of Pulmonology  
NESCOM Hospital, Islamabad

## **Dr. Mashaal Sabqat**

Assistant Professor Medical Education IIMC  
And Riphah International University, Islamabad

# Acknowledgement from the Chair, Committee for Community Acquired Pneumonia guidelines development

---

Alhamdulillah, we have tried our best to fulfil the task assigned to the committee by Chair Guidelines Committee for developing PCS guidelines on different important topics related to chest diseases.

It took around 08 months of hectic efforts, sleepless nights, countless discussions, research, refinement, reviews, and collective insights, but we managed to shape up a comprehensive document.

This guideline is a living one, like all medical issues, subject to improvement in the light of new research. It also covers a yet un-tapped aspect: roadmap for implementation by the health authorities. This requires will for gradual implementation, to avoid undue treatment protocols by both the local uninformed doctors as well as the patients.

I am thankful to all the committee members, Prof Masood ul Haq, Prof Muhammad Irfan, Prof Imran, Prof Irfan Malik, Dr Madiha Siddiqui, and Dr Rizwan Athar, for their dedication, and efforts in improving the document. I would especially like to thank Prof Masood ul Haq and Prof Muhammad Irfan who took time, went through the whole document, and suggested corrections.

I would also like to thank Dr Mashaal Sabqat, Assistant Prof Medical Education IIMC and Riphah International University for her technical help and proof reading the whole document.

Lastly, I hope that those who read it may learn and apply to help their patients, in a more scientific manner. After all, that is what this whole exercise is all about.

Happy reading.

**Prof. Muhammad Zill-e-Humayun Mirza**

Chair, CAP Guideline development Committee  
Pakistan Chest Society

# National Guidelines for Community-Acquired Bacterial Pneumonia in Adults – Pakistan

## Chapter 01: Introduction

---

The low and middle-income countries in the South and Southeast Asia, including Pakistan, face CABP (Community-Acquired Bacterial Pneumonia) as a major public health challenge<sup>1</sup>. Recent regional data suggest that over 1 million adult deaths annually in Asia are attributable to CAP (Community-Acquired Pneumonia), with the most affected being the elderly and patients with comorbidities<sup>2</sup>.

Pakistan's adult population faces a growing but under-recognized burden of CAP<sup>3</sup>. Integrated Disease Surveillance and Response (IDSR) Report by the National Institute of Health, Islamabad indicates pneumonia as the leading cause of deaths due to acute respiratory illness, with notable seasonal peaks in the winter months<sup>4</sup>. Key contributors to this burden include high levels of ambient air pollution (PM<sub>2.5</sub> often exceeding 80 µg/m<sup>3</sup><sup>5</sup>), tobacco use (27% of adults in Pakistan smoke or use smokeless tobacco<sup>6</sup>, unregulated antibiotic access, low influenza and pneumococcal vaccination coverage, and insufficient diagnostic services<sup>6</sup>. An analysis of hospitalized CAP patients in Pakistan showed an overall in-hospital mortality of 10.8%, increasing to 34.5% in older adults and patients with multiple comorbidities<sup>3</sup>. Delayed antibiotic initiation, irrational empiric therapy<sup>7</sup>, and underutilization of severity scoring tools like CURB-65 are the key predictors of poor outcomes<sup>8</sup>.

Despite the availability of local guidelines from the Pakistan Chest Society (PCS)<sup>9</sup>, real-world adherence remains suboptimal. Studies from both public and private hospitals in urban and rural areas of the country have reported wide variations in empirical antibiotic selection, with frequent overuse of fluoroquinolones and third-generation cephalosporins, often without microbiological confirmation<sup>7</sup>. Over-the-counter antibiotic access further worsens resistance patterns and delays appropriate management. Data from the SOAR (Survey of Antibiotic Resistance) program and tertiary care antibiograms consistently show alarming trends of resistance to macrolides, penicillin and cephalosporins among *Streptococcus pneumoniae* isolates in Pakistan<sup>10</sup>.

In addition, the role of viral co-infections, particularly influenza A, RSV, SARS-CoV-2, and parainfluenza, in worsening the infections is increasingly recognized<sup>11</sup>. A Karachi-based study revealed viral-bacterial co-infection in 92.2% of CAP cases, significantly associated with higher ICU admissions and prolonged hospital stay<sup>12</sup>. This highlights the need for improved pneumonia diagnosis by the integration of viral surveillance. In this regard, the 2025 American Thoracic Society (ATS) guidelines recommend considering lung ultrasound as a reasonable alternative to chest X-ray in diagnosing CAP, especially where radiology access is limited<sup>13</sup>. Moreover, the ATS supports withholding antibiotics in otherwise healthy outpatients without any co-morbidities, with clear viral etiology based on clinical judgment.

For stable patients, a shorter antibiotic course (3–5 days) is recommended to reduce resistance risk<sup>13</sup>. These recommendations reinforce the need for improved diagnostic processes and targeted therapy in settings like Pakistan with issues like antibiotic overuse and resistance.

In response to this urgent need, the Pakistan Chest Society (PCS) has developed these National Guidelines for CAP in Adults - 2025. This document utilizes the GRADE methodology and PICO framework, ensuring recommendations are evidence-based, actionable and context-specific.

**These guidelines are:**

1. Informed by more than 50 local studies and surveillance datasets published between 2005 and 2025.
2. Supplemented by regional experiences from India, Bangladesh, Sri Lanka, and the Middle East.
3. Benchmarked against international guidance from the BTS 2023, Indian Chest Society 2023, Canadian Thoracic Society, and ERS/IDSA guidelines.

**These guidelines aim to:**

1. Standardize the diagnosis, risk stratification, and treatment of CAP across Pakistan.
2. Reduce mortality and improve treatment outcomes in both urban and rural populations.
3. Optimize antibiotic usage to combat rising antimicrobial resistance.
4. Establish national KPIs (Key Performance Indicators) for quality monitoring and future updates.
5. Endorsed by the Pakistan Chest Society, this protocol is intended to serve as the official reference document for CAP management in Pakistan and shall be updated periodically as new evidence becomes available.

## Chapter 02:

### Epidemiology and Etiology of CAP in Pakistan

---

CAP is a major public health concern in Pakistan, contributing significantly to morbidity, mortality, and healthcare burden. The epidemiology of CAP in Pakistan is shaped by many factors, including high rates of air pollution, increasing tobacco use, overcrowded living conditions, undernutrition, and rising antimicrobial resistance.

#### **National Burden and Incidence**

The true incidence of CAP in adults in Pakistan remains underestimated due to diagnostic limitations and inconsistent reporting. However, data extrapolated from tertiary hospital-based studies and provincial surveillance indicate an incidence of 75 - 120 cases per 100,000 adults per year, with seasonal peaks between November and February due to increased respiratory viral co-infections<sup>14</sup>.

A recent multi-center cohort (2022–2024) covering five major provinces recorded an overall in-hospital mortality of 9.6% among adults with CAP, with higher mortality rates in Sindh (11.2%) compared to Punjab (7.8%).

#### **Factors associated with a higher mortality included<sup>15</sup>:**

1. Age > 65 years
2. Chronic lung disease (e.g., COPD, bronchiectasis)
3. Diabetes mellitus, chronic kidney disease
4. Indoor air pollution (solid biomass use)
5. Tobacco exposure (national smoking prevalence ~27%)
6. Multi-lobar radiological involvement
7. Studies show greater prevalence in males (male: female ratio ~1.4:1), likely due to differential smoking rates and occupational exposure.

### Microbial Etiology in Adults

Multiple Pakistani studies, including meta-analyses, have explored the etiology of CAP among hospitalized adults, though most are from urban tertiary centers. A 2025 pooled analysis of 4,218 cases from Karachi, Lahore, Peshawar, and Quetta identified the following predominant pathogens<sup>16</sup>:

1. Streptococcus pneumoniae - 15% (most common pathogen overall)
2. Pseudomonas aeruginosa - 11% (higher in patients with structural lung disease or ICU stay)
3. Haemophilus influenzae - 9% (predominantly non-typeable strains)
4. Staphylococcus aureus - 8% (MRSA estimated at ~11% of isolates)
5. Klebsiella pneumoniae - 7% (especially in elderly and diabetic patients)
6. Legionella pneumophila <2% (rarely tested outside major centers)<sup>7</sup>.

Emerging data also highlights an increase in ESBL-producing Enterobacterales in ICU patients (13.4%), with 43% developing pneumonia<sup>17</sup>.

### Viral Co-Infections and Emerging Respiratory Pathogens

Recent research from Karachi, Lahore, and Islamabad has shown increasing detection of respiratory viral co-infections in adult CAP, particularly:

1. Influenza A (H1N1, H3N2) - seasonal surges
2. Rhinovirus/Enterovirus
3. RSV and Parainfluenza
4. SARS-CoV-2 - declining but relevant for differential diagnosis

A 2025 study using multiplex PCR panels in hospitalized CAP patients found that 12.2% had co-detection of viral and bacterial pathogens, with higher mortality (28.6%) observed in this group<sup>18</sup>.

### Geographic Variability and Data Gaps

The bulk of microbiological studies come from urban tertiary care centers, with limited data from rural Sindh, Balochistan, Gilgit-Baltistan, and southern Punjab. Standardized, multicenter surveillance using uniform diagnostics (blood/sputum cultures + antigen tests + viral PCR) is urgently needed to build a national CAP picture.

### Risk Factors for CAP in Pakistan

Category	Key Risk Factors
Host-related	Age > 65, COPD, asthma, diabetes, CKD, immunosuppression, malnutrition
Environmental	Smoking, air pollution (PM2.5 >80 µg/m <sup>3</sup> ), biomass fuel, crowded housing
Healthcare-related	Prior antibiotic use, hospitalization within last 90 days, under- vaccination
Socioeconomic	Delayed care-seeking, financial barriers, low health literacy

## Chapter 03:

### Antimicrobial Resistance (AMR) Trends and Empiric Treatment Challenges in CAP – Pakistan Context

---

Antimicrobial resistance (AMR) poses a growing threat to the effective treatment of CAP in Pakistan. Over the past 15 years, over-the-counter antibiotic availability, inappropriate prescribing practices, poor diagnostic infrastructure, and limited antibiotic stewardship have led to significant resistance among firstline respiratory pathogens.

#### AMR in *Streptococcus pneumoniae*

Macrolide resistance exceeds 25%<sup>7</sup>, which is the threshold used in international guidelines to discourage monotherapy. Nonetheless, macrolides remain commonly prescribed empirically, particularly in outpatient settings.

#### AMR in *Haemophilus influenzae*

1. Ampicillin resistance: 18-25%
2. Macrolide resistance: ~15-20%
3. Amoxicillin-clavulanate and cefuroxime: >95% susceptibility<sup>19</sup>

#### Gram-Negative Resistance – *K. pneumoniae* and *P. aeruginosa*

This pattern reflects frequent misclassification of healthcare-associated strains as community-acquired and highlights the need for thorough clinical risk assessment when choosing empirical antibiotics<sup>20</sup>.

#### Inappropriate Empiric Therapy and Its Consequences

1. Macrolide monotherapy persists despite resistance >30%.
2. Overuse of fluoroquinolones is common.
3. Empiric regimens are often not adjusted based on culture or clinical response<sup>21</sup>.
4. Treatment failure, prolonged hospital stays, and ICU transfers are linked to initial inadequate therapy<sup>17</sup>.

## Chapter 04:

### Risk Stratification and Severity Assessment in CAP

---

Timely and accurate risk stratification in patients with CAP is essential to guide clinical decisions, such as:

1. Site of care (outpatient vs. hospitalization)
2. Need for ICU admission
3. Empirical antibiotic selection
4. Use of supportive care (oxygen, fluids, early escalation)

Severity scoring tools enable physicians to standardize care, reduce unnecessary admissions, and identify high-risk patients who may benefit from early intensive therapy<sup>22</sup>.

#### **CURB-65 and CRB-65: The Most Common Tools in Pakistan**

The CURB-65 score is widely recommended by international and regional guidelines, including those from the BTS<sup>23</sup>, Indian Chest Society<sup>24</sup>, and PCS Pakistan<sup>9</sup>.

It includes:

1. Confusion
2. Urea >7 mmol/L
3. Respiratory rate  $\geq 30$ /min
4. Blood pressure (SBP <90 mmHg or DBP  $\leq 60$  mmHg)
5. Age  $\geq 65$  years

Each component scores 1 point, with a total range of 0–5:

1. 0–1: Low risk (outpatient management)
2. 2: Consider short hospital stay or close monitoring
3. 3–5: High risk (hospitalization or ICU)

The CRB-65 version omits serum urea, making it more feasible in resource-limited or primary care settings<sup>25</sup>. This version is particularly useful in rural Pakistani setups and BHUs without immediate lab access.

Despite the utility and feasibility of its use, a nation-wide study found disagreement between CURB-65 recommendation and physician's decision regarding hospitalization of CAP patients in almost four out of every 10 patients<sup>26</sup>.

#### **PSI (Pneumonia Severity Index)**

The PSI score, developed by Fine et al.<sup>27</sup> uses 20 variables to calculate mortality risk and recommend site of care. While more comprehensive than CURB-65, PSI has limited utility in majority of Pakistani hospitals due to:

1. Complexity
2. Need for laboratory and radiographic data
3. Time burden in busy emergency settings<sup>28</sup>

Although numerous studies have demonstrated that PSI is superior to CURB-65 in predicting mortality among patients with CAP<sup>29,30</sup>, its use in Pakistan is limited due to time and resource constraints. Consequently, CURB-65 and CRB-65 continue to be the preferred tools in routine clinical practice in Pakistan.

### **SMART-COP and SCAP Scores**

Alternative tools like SMART-COP and SCAP have been explored in India and Bangladesh to identify patients needing ICU admission. These tools include:

SMART-COP: Predicts need for intensive respiratory or vasopressor support (IRVS)

SCAP: Spanish tool used for ICU prediction.

A 2022 study from India<sup>31</sup> found that SMART-COP had a higher PPV (Positive Predictive Value) for predicting ICU need (69.8%) compared to CURB-65 (36.5%). However, no large-scale validation of SMART-COP has been conducted in Pakistan to date.

### **Limitations and Local Adjustments**

Despite their value, severity scores must be interpreted in clinical context. Multiple Pakistani and regional studies have highlighted their limitations:

1. Young patients with multi-lobar disease may be under-triaged by CURB-65.<sup>32</sup>
2. Malnourished or diabetic patients may have poorer outcomes despite low scores.
3. In Pakistan, biomarkers like CRP and procalcitonin are rarely available at point-of care.

Moreover, early warning signs such as oxygen saturation <90%, confusion, or RR ≥30 should trigger immediate escalation regardless of score.<sup>33</sup>

To improve relevance, some hospitals in Karachi now combine CRB-65 with SpO<sub>2</sub> <90% as a red flag for immediate referral.<sup>34</sup>

# Chapter 05:

## Evaluation and Diagnostic Work up in CAP

---

Early and accurate diagnosis of CAP is essential to initiate appropriate empirical antibiotic therapy, stratify disease severity, detect atypical or resistant pathogens, and improve patient outcomes. In Pakistan and similar regional contexts, diagnostic limitations such as poor microbiological facilities, late hospital presentation, and over-the-counter antibiotic use often result in the prescription of empirical therapy without pathogen confirmation, increasing the risk of antimicrobial resistance and treatment failure.<sup>7,20</sup>

### Clinical Evaluation

The first step in diagnosis remains a clinical suspicion based on common presentation:

1. Cough with or without purulent sputum.
2. Fever  $\geq 38^{\circ}\text{C}$
3. Dyspnea or pleuritic chest pain
4. Auscultatory findings: bronchial breathing, crepitations, dullness to percussion

A prospective observational study from Peshawar (2022) found that the presence of  $\geq 3$  of these clinical features had a sensitivity of 92% for radiologically confirmed CAP<sup>35</sup>. These findings align with regional data from India and Bangladesh, reinforcing the value of thorough bedside evaluation in low resource settings<sup>36</sup>.

### Radiological Assessment

- Chest X-ray (CXR)

A posterior-anterior chest X-ray remains the primary radiologic modality for diagnosing CAP. Typical findings include lobar consolidation, interstitial infiltrates, and pleural effusions.

In Pakistan, access to CXR is generally available in urban and tertiary centers but often delayed or unavailable in rural hospitals due to equipment issues or staffing constraints.<sup>37</sup>

An Islamabad survey in 2022 found that in 31% of hospitalized pneumonia cases, a chest X-ray was not obtained prior to initiating antibiotics, primarily due to late-night admissions, equipment malfunction, or unavailability of radiology staff.<sup>38</sup>

- Chest CT Scan

High-resolution computed tomography (HRCT) is superior to Chest X-ray in identifying multi-lobe disease, cavitations, necrotizing pneumonia, or alternative diagnoses like malignancy.

Due to its cost and limited availability, HRCT in Pakistan is reserved for patients who fail to improve on standard therapy, show atypical radiological findings, or are suspected of having complications such as empyema<sup>38</sup>.

- USG Chest

An exciting tool in the hands of the trained, with focused algorithms like The Blue Protocol and FAST scans, aim to provide POCUS (point of care ultrasound) as a definitive bedside diagnostic test.

However, cost, training and acceptance make immediate availability and recommendation difficult. A slow roll out with training workshops, and involvement of philanthropic societies may bring this closer to reality.

### **Microbiological Testing**

#### **Sputum Gram Stain and Culture**

Sputum microscopy and culture are basic yet underutilized diagnostic tools. Valid samples have <10 squamous epithelial cells and >25 polymorphonuclear cells per low power field. Processing within 1 hour increases yield. A 2022 study from Lahore reported that only 26% of admitted CAP patients had sputum cultures obtained before starting antibiotics<sup>39</sup>.

Barriers include:

1. Inappropriate sample timing
2. Prior antibiotic use
3. Poor sample quality
4. Lack of lab capacity in district and secondary hospitals

- **Blood Cultures**

Blood cultures are strongly recommended in moderate to severe CAP, especially for febrile, hypotensive, or immunocompromised patients.<sup>40</sup> In Pakistan, blood culture yield remains low (~5–9%), but when positive, it aids in detecting bacteremia with *Streptococcus pneumoniae*, *Staphylococcus aureus*, or *Klebsiella pneumoniae*, including multidrug-resistant strains<sup>40</sup>. Another local study shows a diagnostic yield of 7–12% in moderate-to-severe CAP.<sup>47</sup>

- **Urinary Antigen Testing**

Urinary antigen detection for *S. pneumoniae* and *Legionella pneumophila* offers rapid, non-invasive diagnosis, with around 85% specificity. However, its availability in public hospitals is limited. It is more routinely used in the private sector (e.g., Shifa International, AKUH) and in ICU settings where typical organisms are not identified or *Legionella* is suspected.<sup>41</sup>

It has limited role in routine adult CAP but is useful in cluster outbreaks and public health investigations.

The British Thoracic Society (BTS) 2023, ATS/IDSA 2019 and Indian Chest Society 2012 all recommend microbiological testing in hospitalized patients, particularly those who are severely ill, immunocompromised, or at risk for drug-resistant pathogens.<sup>23,24,48</sup>

### **Biomarkers**

- **C-Reactive Protein (CRP) and Procalcitonin (PCT)**

Biomarkers can assist in differentiating bacterial from viral pneumonia and guide duration of therapy.

CRP is inexpensive and available in most tertiary setups. A 2024 study from Peshawar showed that CRP > 5mg/dL had 87.77% sensitivity and 53.94% specificity in differentiating bacterial from viral pneumonia<sup>42</sup>.

Procalcitonin (PCT) access is limited to advanced hospitals but is more specific for bacterial infections. A Southeast Asian expert-based consensus documented that PCT-guided antibiotic protocols reduced average antibiotic exposure by 34.8% by 1.8 days without compromising safety.<sup>43</sup>

Despite the benefits, cost constraints and lack of lab infrastructure limit routine biomarker usage in Pakistan's secondary and rural hospitals.

### **COVID-19 and Respiratory Viral Co-infections**

Since the onset of COVID-19, it has become essential to rule out SARS-CoV-2 in patients presenting with pneumonia-like symptoms. Recent guidelines recommend performing an RT-PCR or rapid antigen test in the initial workup, especially during high-prevalence seasons.<sup>44</sup>

Moreover, Pakistani, and South Asian data increasingly show co-infections with influenza, RSV, or rhinovirus among CAP cases, supporting the need for broader viral panels in critically ill patients.<sup>45</sup>

### **Diagnostic Gaps in Pakistan**

Multiple audits and field studies indicate persistent gaps in diagnostic implementation:

1. <30% of admitted CAP cases have microbiological confirmation.
2. 70% of patients receive empirical antibiotics before diagnostic samples are taken<sup>8</sup>

Diagnostic tools like CT scans, antigen tests, and biomarkers are inaccessible in most public hospitals. No national protocol exists for standardizing diagnostic workup in pneumonia patients.

### **PCS Recommendations to Address Gaps**

To optimize diagnostic accuracy and antibiotic stewardship in CAP, the Pakistan Chest Society recommends<sup>9</sup>:

1. Early sample collection before starting empirical antibiotics.
2. Standardized sputum and blood culture protocols in all moderate/severe cases
3. Wider availability to ensure routine use of CRP and/or PCT, where feasible to help avoid overtreatment
4. Broader availability of urinary antigen testing and multiplex PCR, especially in ICU patients or during outbreaks.
5. Periodic audits and national training programs to improve diagnostic consistency

## Chapter 06:

# Empirical Antibiotic Therapy and Treatment Algorithm for CAP in Pakistan

---

Effective empiric treatment of CAP must balance:

1. Local pathogen prevalence
2. Antibiotic resistance trends
3. Patient risk category (outpatient, inpatient non-ICU, ICU)
4. Access and cost considerations in the Pakistani healthcare system

Numerous Pakistani studies confirm that antibiotic regimens designed for high-income countries are often inappropriate due to Pakistan's high rates of antimicrobial resistance and significant burden of Gram-negative organisms, especially in moderate and severe community cases.<sup>7,21</sup>

National and international guidelines (PCS, BTS 2023, Indian Chest Society 2023) uniformly recommend localized empirical strategies that reflect microbiological realities and healthcare infrastructure.<sup>9,23,24</sup>

### Principles of Empirical Therapy in CAP

Before selecting empirical antibiotics, clinicians must:

1. Assess disease severity using CRB-65 or CURB-65 (Section 4)
2. Review hospital or city-level antibiograms
3. Consider comorbidities (diabetes, COPD, CKD)
4. Evaluate risk factors for drug-resistant pathogens (see 6.2)

### Risk Factors for Drug-Resistant Pathogens (DRPs)

Pakistan-specific surveillance reveals that 40–45% of hospitalized CAP patients harbor drug-resistant organisms, such as ESBL-producing *Klebsiella pneumoniae* or *Pseudomonas aeruginosa*.<sup>7</sup>

Key risk factors include:

1. Hospitalization within the past 90 days
2. Prior use of antibiotics in the past 3 months
3. Chronic lung diseases (COPD, bronchiectasis)
4. Structural lung disease, CKD, or malignancy
5. Tube feeding, aspiration risk
6. Known colonization with MDROs

Patients with  $\geq 2$  of these risk factors require extended-spectrum or dual therapy regimens.

### Pakistani Empirical Treatment Algorithm (Adult CAP)<sup>46</sup>

A. Outpatient (Low Risk, CRB-65 = 0–1, No DRP Risk)

1. Amoxicillin 1 g PO TID, OR Doxycycline 100 mg PO BID  $\times$  5–7 days or
2. Amoxicillin-clavulanate 625 mg PO TID in case of mild comorbidities or
3. Cefpodoxime 200 mg PO BID  $\times$  5 days.

Note: Avoid macrolide monotherapy due to high resistance (macrolide resistance >30% in *S. pneumoniae*).

**B. Outpatient (Moderate Risk or DRP Risk Factors Present)**

1. Amoxicillin-clavulanate PO, OR Doxycycline 100 mg PO BID or
2. Levofloxacin 750 mg PO OD × 5–7 days or
3. Cefuroxime 500 mg PO BID + Azithromycin 500 mg Od 11
4. Cefpodoxime 200 mg PO BID × 5 days.

Caution: Fluoroquinolones should be avoided in patients at risk of QT prolongation or with cardiovascular history.

**C. Inpatient (Non-ICU)**

1. Ceftriaxone 1–2 g IV OD + Azithromycin 500 mg IV/PO OD or
2. Levofloxacin 750 mg IV OD if beta-lactam allergy.

**D. Inpatient (Severe/ICU or DRP Risk)**

1. Cefepime 2 g IV q8h + Azithromycin 500 mg IV OD or
2. Piperacillin-tazobactam 4.5 g IV q6h + Levofloxacin 750 mg IV OD
3. Monotherapy with a Carbapenem.

Additions based on risk:

1. MRSA suspicion: Add Vancomycin 15 mg/kg IV BID or Linezolid 600 mg IV BID
2. Pseudomonas suspicion: Avoid ceftriaxone; use anti-pseudomonal β-lactam.

**Duration of Therapy**

1. Outpatients: 5–7 days if stable and clinically improving
2. Inpatients: 7–10 days depending on severity
3. Shorter duration (≤5 days): May be used in patients with mild-moderate disease if PCT-guided and showing rapid clinical recovery

**Role of Antimicrobial Stewardship**

Inappropriate empirical therapy is a key driver of AMR and poor outcomes. A 2022 multi-center audit reported:

1. 39% of CAP patients received non-guideline-concordant empiric therapy
2. Patients receiving inappropriate empiric treatment had a 2.6 times higher mortality rate
3. Duration of therapy exceeded recommended limits in 42% of cases<sup>20</sup>

Antimicrobial stewardship programs (ASPs), where implemented, showed a 25% reduction in inappropriate antibiotic use and shorter hospital stays.

**Pakistan-Specific Algorithm (Simplified Table)**

**Table 6.1 – Empirical Antibiotic Algorithm (CAP – Adults, Pakistan)**

Risk Stratification	Recommended Empirical Therapy
Outpatient (Low Risk)	Amoxicillin Or Amox-Clav ± Doxycycline. Or Cefpodoxime
Outpatient (DRP Risk)	Levofloxacin OR Cefuroxime + Azithromycin or Cefpodoxime
Inpatient (Ward)	Ceftriaxone + Azithromycin OR Levofloxacin
ICU or Severe + DRP Risk	Pip-Tazo + Levofloxacin ± MRSA coverage

## Chapter 07:

# Microbiological Confirmation and Antimicrobial Stewardship Strategy

---

Microbiological confirmation in CAP plays a pivotal role in guiding targeted antibiotic therapy, limiting the overuse of broad-spectrum agents, and mitigating antimicrobial resistance (AMR). Despite its clinical significance, microbiological testing remains underutilized across most healthcare tiers in Pakistan.<sup>47</sup>

Timely collection of good-quality sputum, blood cultures, and in selected cases, urinary antigen tests or molecular panels, can lead to pathogen identification in 25-40% of CAP cases<sup>31,34</sup>. This distinction is critical to identify true community-acquired multidrug-resistant (MDR) pathogens (e.g., ESBL or carbapenem-resistant *Klebsiella*) versus colonizing hospital flora.

### Gaps in Pakistan's Microbiology Practices

Despite formal guidelines and internal hospital protocols, microbiology remains poorly integrated into the standard diagnostic pathway for CAP.

Key barriers include:

1. Delays in specimen processing (especially during night shifts or weekends)
2. High rejection rate of sputum samples due to poor collection techniques
3. Inadequate documentation or failure to order cultures at ER/OPD level
4. Minimal training of interns, nurses, and paramedics
5. Absence of culture-based decision incentives for physicians

A study at Lahore General Hospital (2022) reported that sputum cultures were omitted in 61% of CAP admissions, and even when cultures were performed, results were delayed beyond 72 hours in 48% of cases.<sup>49</sup>

Conversely, a study using culture sensitivity reports to optimize antibiotic prescriptions in Lahore demonstrated culture-guided modification in more than 70% patients.<sup>39</sup>

### Role of Antimicrobial Stewardship (AMS)

AMS is central to optimizing treatment, minimizing resistance, and reducing mortality.

The long-term viability of antimicrobial stewardship programs (ASPs) in Pakistan is challenged by systemic issues such as the absence of mandatory implementation for accreditation, inadequate administrative support, limited microbiology and IT infrastructure, and a shortage of key personnel.<sup>50</sup>

### Regional Models of AMS and Microbiology Integration

India: The AMR containment program launched in 2021 emphasized hospital level antibiogram updates every quarter and automated flagging of discordant

antibiotic prescriptions. A 2024 survey showed a 17% reduction in carbapenem use in high-burden respiratory wards<sup>51</sup>.

Sri Lanka: In 2021, tertiary hospitals adopted CRP- and PCT-guided AMS protocols, achieving shorter antibiotic durations by 2.1 days and reducing ICU transfers for CAP by 22%.<sup>52</sup>

These regional examples highlight the feasibility of implementing AMS in LMICs with limited budgets through policy commitment, audit, and lab integration.

### **Future Directions for Pakistan**

For sustainable microbiological confirmation and stewardship in CAP, Pakistan must implement:

1. Regional antibiogram networks coordinated by NIH and PCS
2. Mandatory submission of drug-resistant isolates for national AMR mapping
3. AMS integration into electronic health records (EHRs)
4. Deployment of ID-trained fellows and stewardship pharmacists at tertiary centers
5. Standardized ER-level admission bundles with checklists for culture ordering

These interventions can significantly improve CAP outcomes and curb the rise in multidrug-resistant community infections.

## Chapter 08:

### Follow-Up, Monitoring, and Patient Outcomes

---

Monitoring patients with CAP is essential for early detection of treatment failure, prevention of complications, and ensuring appropriate transition to oral therapy or discharge. Local, regional, and international guidelines emphasize structured follow-up strategies tailored to patient severity, comorbidities, and response to therapy.

Given the infrastructure and access limitations, a pragmatic, cost-effective model for CAP monitoring in Pakistan is as follows:

#### Early Reassessment

Initial clinical reassessment is recommended within 48–72 hours after starting empirical antibiotics. A comparative study from Lahore (2022) found that 65% of CAP patients taking amoxicillin and 62% of those taking Azithromycin showed improvement by day 3 and did not require change in antibiotics or escalation of care<sup>53</sup>, validating the 72-hour review model.

Key parameters to reassess include:

1. Temperature trend (resolution of fever)
2. Respiratory rate and oxygen saturation
3. Hemodynamic status
4. Mental status (GCS or alertness)
5. Inflammatory markers (CRP, PCT – if available)
6. Radiological status (only if deterioration suspected)

#### Imaging During Hospitalization

Both the British Thoracic Society<sup>23</sup> and IDSA/ATS<sup>48</sup> guidelines recommend against routine daily chest X-rays unless there is clinical worsening. However, a 2018 study in tertiary care hospitals in Karachi reported that 47% of hospitalized CAP patients underwent daily CXR<sup>54</sup>, adding unnecessary cost and radiation burden without clinical benefit.

#### Criteria for IV-to-Oral Switch and Discharge

Patients can safely transition to oral antibiotics and be discharged once they meet all the following criteria:

1. Afebrile for  $\geq 48$  hours
2. Hemodynamically stable (BP  $\geq 90/60$ mmHg, HR  $< 100$ /min)
3. Tolerating oral intake
4. No signs of clinical deterioration
5. Mental status at baseline

A 2023 study found that step-down therapy after 3–4 days of IV antibiotics had outcomes equivalent to prolonged IV therapy, provided switch criteria were met.<sup>55</sup>

### **Radiological Follow-Up Post-Recovery**

The BTS 2023 guidelines recommend that patients >50 years old or those who smoke should receive a repeat chest X-ray at 6 weeks post-recovery to rule out malignancy or chronic lung disease.<sup>23</sup>

A 2015 study<sup>56</sup> found that 3.2% of patients admitted with CAP who had apparent radiological resolution were subsequently diagnosed with lung cancer or bronchiectasis on 6-week follow-up CT.

We recommend repeating chest X-rays at 6 weeks to rule out malignancy or chronic lung disease unless it is indicated earlier due to poor therapeutic response or any complication is suspected.

### **Outcomes and Mortality Trends**

A national multicenter study in Karachi showed:

1. In-hospital CAP mortality: 8.4% overall
2. ICU subgroup mortality: 23.1%
3. Mortality correlated with CURB-65  $\geq 3$ , presence of DRPs, late hospital presentation, and lack of microbiological guidance<sup>35</sup>

These patterns highlight the role of early diagnosis, empiric accuracy, and follow-up in improving survival.

These guidelines recommend monitoring the outcome and mortality trends locally (at institution levels), regionally and nationally. These patterns will provide evidence to be incorporated in future guidelines to improve management strategies.

### **Post-Discharge Planning and Readmission Prevention**

Structured follow-up and patient education significantly reduce readmission and complications. A 2025 systematic review of 11 RCTs (Randomized Controlled Trials) found that structured discharge counselling reduced 30-day readmission by 28%,<sup>57</sup> by improving adherence and warning sign recognition.

Key elements of discharge and follow-up strategy:

1. Review of antibiotic course, side effects, and adherence.
2. Reinforcement of warning signs (dyspnea, hemoptysis, fever rebound).
3. Follow-up appointment within 2-4 weeks for elderly, COPD, diabetic patients.
4. Repeat CXR at 6 weeks, if not fully recovered, especially in chronic lung patients.
5. Smoking cessation and influenza/pneumococcal vaccination advice where applicable.

### **Recommendations**

To ensure consistent monitoring and safe outcomes in CAP patients:

1. Include standardized follow-up templates in discharge summaries.
2. Designate a follow-up contact point (clinic or phone) for readmission triage.
3. Use electronic flags or reminder systems (if EMR is available) for radiologic follow-up.
4. Conduct periodic audits of mortality, readmission, and IV-to-PO switch rates as performance indicators.

## Chapter 09:

# Special Populations in CAP Management

---

Certain populations, including the elderly, immunocompromised individuals, and pregnant women, present unique diagnostic, and therapeutic challenges in the management of CAP. These subgroups exhibit atypical clinical presentations, greater susceptibility to complications, and often require dose and drug-specific considerations due to altered pharmacokinetics and comorbidities.<sup>58-60</sup>

### Elderly Patients

Adults over 65 years account for an estimated 22-27% of CAP hospital admissions in Pakistan. A 2019 study in Karachi reported a 1.7-fold higher in hospital mortality in this age group compared to younger patients.<sup>3</sup> Common atypical presentations include:

1. Acute confusion
2. Lethargy
3. Decreased oral intake

Management Considerations:

1. Avoid nephrotoxic agents (e.g., aminoglycosides)
2. Minimize QT-prolonging drugs (e.g., fluoroquinolones), especially in those with electrolyte imbalance or diuretic use
3. Dose adjustment based on creatinine clearance is critical

A cross-sectional multi-center study in Lahore reported that 17% of elderly patients experienced preventable drug-related complications due to unadjusted renal dosing, resulting in longer hospitalization.<sup>61</sup>

### Immunocompromised Patients

This group includes:

1. Patients with hematologic malignancies or solid tumors
2. Transplant recipients
3. Advanced HIV/AIDS patients
4. Uncontrolled diabetes mellitus
5. Long-term corticosteroid or biologic therapy users

A Lahore-based study (2016) of 100 CAP cases in oncology patients reported multidrug-resistant pathogens (e.g., ESBL-producing *Klebsiella pneumoniae*, MDR *Pseudomonas*) in 36% of isolates.<sup>62</sup> Clinical features may be atypical:

1. Minimal radiological infiltrates
2. Absence of fever or leukocytosis
3. Rapid hypoxia or septic shock

- Treatment Guidelines:
1. Empirical regimens: Piperacillin-tazobactam or Cefepime
  2. Add Vancomycin or Linezolid if MRSA risk
  3. Bronchoscopy with BAL should be considered early (within 72 hrs.)

A 2022 Indian study from Delhi showed improved survival with early bronchoscopy in immunocompromised CAP cases.<sup>63</sup>

## Pregnant Women

Physiological changes in pregnancy such as diaphragmatic elevation, reduced FRC, increased oxygen demand, and altered immunity predispose women to more severe pneumonia.

A cohort from Ayub Medical College, Abbottabad reported a 17% incidence of development of sepsis among pregnant women admitted with CAP.<sup>64</sup>

Recommended antibiotics:

1.  $\beta$ -lactams (e.g., ceftriaxone)
2. Macrolides (e.g., azithromycin)
3. Amoxicillin-clavulanate Avoid:
  - Fluoroquinolones (risk of fetal cartilage damage)
  - Tetracyclines (hepatotoxicity, fetal teeth discoloration)

Admission is warranted for:

- Respiratory rate  $\geq 30$ /min
- SpO<sub>2</sub> <94%
- Tachycardia or hypotension
- Signs of fetal distress or preterm labor

Middle Eastern data (e.g., from UAE and KSA) corroborate increased ICU admission rates in pregnant CAP patients, highlighting the importance of early hospitalization and multidisciplinary care.<sup>65</sup>

## National and International Recommendations for High-Risk Groups

The British Thoracic Society 2023<sup>23</sup>, IDSA/ATS 2019<sup>48</sup>, Canadian Thoracic Society (CTS)<sup>66</sup> and Pakistan Chest Society (PCS)<sup>9</sup> guidelines advocate for tailored diagnostic and treatment pathways in these high-risk groups. These include Specialist consultation (geriatrics, ID, obstetrics):

1. Close renal and hepatic monitoring
2. Earlier use of diagnostic tools (CRP, procalcitonin, sputum culture)
3. Adjustment of empirical therapy to reduce toxicity risk

In Pakistan, implementation of such protocols remains inconsistent.

## Urgent Needs in Pakistan

To optimize CAP outcomes in special populations, the following interventions are recommended:

1. Clinical decision-support tools tailored for elderly patients (e.g., renal dose calculators, QT risk scoring systems)
2. Posters or charts listing pregnancy-safe antibiotics in ERs and internal medicine wards
3. CME modules for junior doctors on atypical presentations and risk-adjusted therapy
4. Creation of national CAP registries to monitor treatment outcomes in vulnerable populations

Such targeted efforts will not only improve patient outcomes but also reduce avoidable complications and mortality in these high-risk cohorts.

# Chapter 10:

## Prevention Practices

---

### **Pneumococcal Vaccination**

The 13-valent conjugate vaccine (PCV13) and 23-valent polysaccharide vaccine (PPSV23) are licensed and available in Pakistan, but remain underutilized in adult practice, even among diabetics, COPD patients, and elderly populations.

The Pakistan Endocrine Society<sup>67</sup> and PCS guidelines<sup>9</sup> recommend PCV13 followed by PPSV23 in all adults  $\geq 65$  years, and adults aged 18–64 with comorbidities such as diabetes, CKD, COPD, and chronic liver disease.

A tertiary-care cohort from Lahore (2022) involving 526 diabetic patients showed that only 7% were vaccinated against pneumococcus.<sup>68</sup> A 2023 Middle eastern clinical review found that the rate of hospitalization in vaccinated Type 2 DM patients with pneumonia was 5%, as compared to 15% in non-vaccinated Type 2 DM patients.<sup>69</sup>

In Hyderabad, India, hospital discharge protocols mandating PCV13 for COPD discharges increased 1-year vaccination coverage from 11% to 47%.<sup>70</sup>

Sri Lanka integrated PCV13 into elder-care centers in Galle and Kandy districts in 2021, leading to a 19% decrease in adult pneumonia-related admissions over 12 months.<sup>71</sup>

The Dubai Health Authority offers PCV free for all Emiratis  $>60$  years, with vaccine uptake  $>70\%$  since 2021.<sup>72</sup>

Pakistan fell well short of regional countries, and it is recommended to promote the pneumococcal vaccine in all vulnerable high-risk groups.

### **Influenza Vaccination**

Annual influenza vaccination plays a crucial role in preventing primary viral illness and secondary bacterial pneumonia, particularly in COPD, elderly, and diabetic populations.

A systematic review of influenza vaccines in Pakistan showed that vaccinated COPD patients had 52% fewer pneumonia-related admissions during influenza seasons, with higher adherence among those counselled at each visit.<sup>73</sup>

A 2022 multicenter cross-sectional study of 400 healthcare professionals in Lahore revealed that only 32% routinely recommended flu vaccines to high-risk patients, citing affordability and availability as barriers.<sup>74</sup>

Bangladesh and Sri Lanka have included flu vaccination in their national essential medicines list, offering subsidized or free access to those 260 years<sup>75,76</sup> and Noncommunicable diseases patients.

The WHO Eastern Mediterranean Office highlights that for every \$1 spent on influenza vaccination, South Asian countries save \$4.5 in direct medical and productivity costs.<sup>77</sup>

Considering the available evidence, a wider coverage of vulnerable population with influenza vaccine is being recommended.

### **Risk Factor Modification**

Multiple modifiable risk factors are well-documented contributors to increased risk of CAP and poor treatment outcome. Addressing such factors has shown to improve the outlook and need to implement more widely.

A 2024 initiative to raise awareness among rural population of Punjab regarding smoking cessation resulted in favorable outcomes.<sup>78</sup>

Faith-based health literacy campaigns in KP and Punjab have shown promise in reducing vaccine hesitancy and promoting smokeless cooking practices.<sup>79,80</sup>

### **Structured Screening and Education**

Innovative models of community outreach and clinic-based preventive care are beginning to demonstrate impact in Pakistan.

Post-discharge pneumonia clinics established in Peshawar and Rawalpindi showed 36% reduction in 90-day readmission for CAP after structured vaccine education and lifestyle counselling.

The GASP model (India) uses SMS-based vaccination reminders and trained community health workers, raising adult pneumococcal vaccination rates from 7% to 28% over 18 months.<sup>81</sup>

Saudi Arabia's e-Hospital app and UAE's SEHA health portal both provide vaccination tracking, eligibility alerts, and risk calculators tailored for pneumonia prevention in older adults.<sup>82</sup>

### **National Policy Recommendations for Pakistan**

Given the emerging evidence and local disease burden, it is essential for health authorities and professional bodies to incorporate preventive care for CAP into national adult medicine policies. The following recommendations are endorsed by the Pakistan Chest Society (PCS), MMIDSP, and senior respiratory faculty:

1. Include PCV13 and annual influenza vaccines in Pakistan's adult immunization framework with prioritization for:
  - a. Adults  $\geq 65$  years
  - b. Patients with COPD, asthma, diabetes, CKD
  - c. Immunosuppressed individuals
2. Implement hospital-based standing orders for pneumococcal and flu vaccines at discharge in pneumonia and COPD admissions
3. Integrate vaccine counselling and tracking into outpatient records (paper or EMR)
4. Launch mass media and religious leader-endorsed vaccine awareness campaigns targeting hesitancy and misinformation
5. Collaborate with provincial health departments to develop regional dashboards for tracking vaccine uptake, pneumonia admissions, and post-discharge readmission
6. Introduce reimbursement/subsidy models under Sehat Card or Ehsaas health plans for adult vaccine access

According to WHO-EMRO's 2017 cost-effectiveness analysis, implementation of these strategies could reduce pneumonia-related hospitalizations in Pakistan by 18–22% over five years.<sup>83</sup>

# Chapter 11:

## Implementation of Framework and National Roll-Out Strategy

Translating evidence-based recommendations into real-world clinical practice across Pakistan requires a structured, phased, and context-sensitive framework. This implementation strategy must address key challenges within the healthcare system: infrastructure variability, urban-rural disparities, limited diagnostics, fragmented information systems, and workforce training gaps.<sup>84</sup>

Historical models across South Asia and LMICs, including India's ICMR-AMR program, Sri Lanka's National DOTS rollout, and Bangladesh's integrated pneumonia care strategy, have highlighted the importance of political endorsement, simplification of clinical tools, and measurable outcome tracking for successful deployment.<sup>85-87</sup>

A Delphi consensus by the Pakistan Chest Society (2023)<sup>88</sup> involving 61 stakeholders identified four critical barriers to CAP protocol implementation:

1. Lack of clinician awareness, especially in secondary and primary care
2. Absence of written, simplified protocols in district hospitals and BHUs
3. Resistance to change among senior clinicians
4. Poor data systems and absence of EMR integration

### Governance and Policy Alignment

Implementation should be formally endorsed by:

1. Ministry of National Health Services, Regulation & Coordination (MoNHSRC)
2. Pakistan Chest Society (PCS)
3. College of Physicians and Surgeons Pakistan (CPSP) and aligned with:
  - WHO Essential Medicines List (2023)<sup>89</sup>
  - National Action Plan (Pakistan, 2021–2025)<sup>84</sup>
  - National Institute of Health (NIH) Pneumonia Surveillance Framework (2023)<sup>84</sup>

### Tiered Roll-Out Strategy

Phase 1 (0–6 months): Tertiary Pilots

1. Implement in 10 major tertiary centers (e.g., AKUH, JPMC, Mayo, Nishtar, KTH)
2. Include EMR-based treatment checklists and audit-ready modules
3. Involve infectious disease specialists and pharmacists in stewardship teams.

Phase 2 (6–12 months): District-Level Expansion

1. Adapt protocols into pictorial, Urdu-translated tools for secondary hospitals
2. Distribute CURB-65 cards, sputum/blood culture checklists, and nurse flowsheets
3. Train medical officers via district health authorities

Phase 3 (12–24 months): Integration at BHUs and RHCs

1. Integrate simplified CAP algorithms into Lady Health Worker and Rural Health Center curricula
  2. Supply "pneumonia kits" (azithromycin, amoxicillin, oral steroids)
  3. Use voice-based tools and mobile alerts for rural settings
- Global models:
- Thailand's Rural Pneumonia Algorithm decreased adult pneumonia mortality by 24%.<sup>90</sup>
  - Ethiopia's Health Extension Worker Strategy reduced pneumonia hospitalization by 18% in highland districts.<sup>91</sup>

### Capacity Building and Digital Training

1. Launch CME-accredited modules via PCS, CPSP, PM&DC for doctors, nurses, and pharmacists
2. Use e-learning and mobile-based platforms, modeled after India's NACOIGNOU HIV program which trained >150,000 providers.<sup>92</sup>

Bangladesh's pneumonia scale-up (2017–2021) showed 42% improvement in protocol adherence after deployment of digital decision aids and nurse educator workshops.<sup>93</sup>

### Monitoring and Evaluation

1. Define CAP Key Performance Indicators (KPIs):
2. Conduct quarterly audits with feedback dashboards, modeled on UAE's CAP stewardship model (LOS reduced from 7.2 to 5.4 days).<sup>94</sup>
3. Assign regional coordination to NIH-Islamabad and PCS provincial chapters
4. Pilot national EHR templates for CAP management at five federal hospitals<sup>95</sup>

### Financing and Procurement

1. Embed CAP protocol implementation in public sector health budgets (2025–2027)
2. Diagnostic supplies: CRP kits, ABG, cultures
3. Human resources: ID physicians, AMS pharmacists
4. Medicines: IV and oral regimens for switch therapy, vaccines
5. Mobilize international donors:

Sri Lanka used Global Fund support to expand TB-pneumonia diagnostic integration<sup>96</sup>; Nepal developed its pneumonia dashboard with WHO-SEARO assistance.<sup>97</sup>

### Community Engagement and Literacy

Collaborate with religious leaders, media outlets, and civil society to promote:

1. Pneumonia vaccination
2. Early care-seeking
3. Rational antibiotic use
4. Deploy Urdu-based audio, leaflet, and mobile education materials via:
5. Lady Health Workers
6. FM radio stations in rural belts
7. Mobile health units and WhatsApp groups

Indonesia's Islamic Health Alliance used madrasa and mosque networks to increase vaccine uptake and explain guideline adherence as "Shariah-aligned" public health actions.<sup>98</sup>

### Global Lessons and Local Adaptation

Country	Implementation Highlight	Outcome
Vietnam	Pneumonia protocol in EMRs	+33% culture rate, –19% ceftriaxone use <sup>99</sup>
Jordan	ICU triage + antibiotic alerts	Reduced CAP ICU mortality <sup>100</sup>
Thailand	Village volunteer network	22% lower readmission <sup>101</sup>

### Summary and Way Forward

Pakistan must adopt a national CAP policy that is:

1. Phased (pilot → scale-up → rural integration)
2. Contextualized (translated, simplified, pictorial)
3. Measured (audited KPIs with feedback)
4. Sustainable (annual revision via a "living guideline" approach)

Only a learning health system model—with real-time data, clinician engagement, and community trust—can sustainably improve CAP outcomes nationwide.

## Chapter 12:

### Research Priorities and Future Directions

---

Despite the significant public health burden posed by CAP in Pakistan, local scientific research is sparse, fragmented, and heavily skewed toward pediatric and TB-related respiratory conditions. Strengthening the research foundation across epidemiology, microbiology, diagnostics, clinical outcomes, and behavioral science is necessary for sustainable improvements in this front.

#### Epidemiological Surveillance

Pakistan currently lacks a prospective, multicenter, ICD-coded surveillance system for adult CAP. Most data are derived from isolated, single-center retrospective studies with limited seasonal or demographic granularity.<sup>102</sup> In contrast:

1. India's ICMR-RespNet program has reported province-wise CAP incidence using standardized electronic case definitions.<sup>103</sup>
2. Sri Lanka's National Surveillance Program routinely publishes annual epidemiological profiles of adult pneumonia by age, gender, and comorbidities.<sup>104</sup>

To bridge this gap, Pakistan should develop a national electronic registry under NIH or PMRC using EHR-integrated tools to map:

1. True incidence of adult CAP
2. Regional seasonality (e.g., monsoon and winter spikes)
3. Geographic and occupational exposure clusters
4. Co-infection with viruses (e.g., influenza, SARS-CoV-2)

#### Microbiological and Resistance Mapping

Currently, no national antibiogram database exists focusing on CAP pathogens. Local studies from Lahore, Karachi, and Peshawar (2015–2023) report variable resistance rates in *Streptococcus pneumoniae*, *Klebsiella pneumoniae*, and *Haemophilus influenzae*.<sup>19</sup> For instance:

1. A multi-center study (2023) reported penicillin resistance in 36% of *S. pneumoniae* isolates from sputum.<sup>105</sup>
2. In Karachi (2022), *Klebsiella* species showed ESBL positivity in 48% of CAP cases.<sup>106</sup>

A sentinel microbiology lab network is urgently needed, linked to Pakistan's National AMR Surveillance Framework, to collate and publish CAP-focused resistance patterns annually.

#### Diagnostic Algorithms and Biomarker Utility

Use of risk assessment tools like CURB-65, PSI, and NEWS2 is inconsistent in Pakistan. A multi-national study across ten cities of Pakistan found that only 32% of physicians used PSI and 34% use CURB-65 for assessment of severity at admission.<sup>107</sup>

Moreover, local validation of biomarkers like C-reactive protein (CRP) and procalcitonin (PCT) for antibiotic de-escalation is lacking:

No prospective study has evaluated PCT-guided therapy for CAP in the Pakistani context, despite increasing use in private hospitals.

Rural hospitals also lack access to CRP, and lung ultrasound remains underevaluated as a point-of-care diagnostic modality for pneumonia.<sup>108</sup>

Well-designed diagnostic utility trials are essential to evaluate:

1. CRP and PCT thresholds for initiation and discontinuation of antibiotics
2. Chest X-ray vs. lung ultrasound vs. CT in diagnostic accuracy
3. Predictive value of scoring systems in urban vs. rural populations

### **Outcome Studies and Therapeutic Trials**

Pakistan has not conducted any randomized controlled trials (RCTs) on:

1. Short-course therapy (e.g., 5 vs. 7 days)
2. Monotherapy vs. combination therapy
3. IV-to-oral switch timing in hospitalized CAP

These questions remain unaddressed despite the prohibitive cost and AMR implications of prolonged or inappropriate therapy.

A prospective ICU registry tracking etiology, severity (CURB-65, SOFA), complications, and mortality is essential to generate local predictive outcome models.

### **Implementation Science and Behavioral Research**

The barriers to evidence implementation in Pakistani hospitals, such as clinical inertia, diagnostic delay, and antibiotic overuse, are often behavioral, not just logistical.

India's CAP rollout (2019–2022) used the COM-B framework (Capability, Opportunity, Motivation–Behavior) to design educational interventions that improved risk score usage and reduced unnecessary IV antibiotics by 32%.<sup>109</sup>

Pakistan needs similar implementation science grants through HEC, NIH, and PCS, focusing on:

1. Clinician knowledge–behavior gaps
2. Antibiotic prescribing motivations
3. Adoption of decision-support tools
4. Urban-rural comparisons in practice behavior

### **Regional Collaboration and Data Sharing**

To strengthen evidence-based CAP policy, Pakistan should actively participate in:

1. WHO GLASS (Global Antimicrobial Resistance and Use Surveillance System)<sup>110</sup>
2. SEARAS (Southeast Asia Regional AMR Surveillance)<sup>111</sup>
3. GCC Infectious Diseases Working Group for regional treatment benchmarking<sup>112</sup>
4. Regional data sharing platforms can facilitate:
5. Pooled antibiograms (e.g., SAARC AMR Network)
6. Regional RCTs on oral switch therapy or vaccine uptake
7. Shared platforms for risk calculators and treatment algorithms

## **Research Coordination and Funding**

To institutionalize CAP research:

1. Launch a National CAP Research Consortium under NIH, PCS, PMRC, and leading academic hospitals.
2. Define national research priorities annually in collaboration with the Ministry of Health and DG Research.
3. Promote open-access publication, particularly for multicenter surveillance and implementation research.

Funding streams may include:

1. PCS-CPSP seed grants
2. WHO-EMRO small research schemes
3. GAVI/USAID innovation grants on diagnostic evaluation

## **Conclusion**

Pakistan's future CAP strategy must be evidence-generating, not just evidence consuming. A coordinated national research roadmap focusing on diagnostics, stewardship, outcome predictors, and behavior change is critical to inform policies and optimize care.

# Chapter 13:

## Summary of Key Recommendations and Algorithmic Pathways

This section distills clinical, diagnostic, therapeutic, and public health guidance from preceding chapters into operational recommendations and clinical algorithms to support uniform national implementation across healthcare levels in Pakistan.

### Summary of Core Clinical Recommendations

#### Definition

CAP is defined as an acute infection of the pulmonary parenchyma acquired outside hospital settings, confirmed by clinical signs (fever, cough, dyspnea) and radiologic evidence of new infiltrates.<sup>113</sup>

#### Common Pathogens

1. Streptococcus pneumoniae (most common)
2. Haemophilus influenzae, Klebsiella pneumoniae
3. Atypical: Mycoplasma pneumoniae, Legionella spp., Chlamydia pneumoniae<sup>114</sup>

#### Severity Assessment

Use CURB-65 or CRB-65 to guide treatment decisions and disposition.

CURB-65  $\geq 2$  is associated with higher mortality and ICU need.<sup>32</sup>

#### Diagnostic Recommendations

1. Chest X-ray (mandatory in all suspected cases) or Lung Ultrasound if available
2. CBC, CRP, and where available, Procalcitonin (PCT)
3. Blood and sputum cultures before initiating antibiotics, especially in inpatients<sup>115</sup>

#### Empirical Antibiotic Therapy (Based on Resistance Trends and Risk Factors)

1. **Outpatient, low-risk:** Amoxicillin-clavulanate or Doxycycline – Avoid macrolide monotherapy due to  $>30\%$  macrolide resistance in *S. pneumoniae*<sup>116</sup>
2. **Moderate severity (ward):** Beta-lactam (e.g., ceftriaxone) + macrolide (e.g., azithromycin), or respiratory fluoroquinolone (e.g., levofloxacin)<sup>116</sup>
3. **Severe/ICU or DRP risk:** Anti-pseudomonal  $\beta$ -lactam (e.g., piperacillin-tazobactam or cefepime) + macrolide  $\pm$  MRSA coverage (e.g., vancomycin/linezolid)<sup>117</sup>

#### Oral Switch & Duration

Switch to oral antibiotics within 48–72 hours if afebrile, hemodynamically stable, and absorbing orally.

Total duration:

1. 5–7 days in stable cases
2. 10–14 days if MDR organisms or complications (e.g., empyema)<sup>118</sup>

#### Vaccination Recommendations

PCV13 + PPSV23 and Influenza vaccine for:

1. Adults  $\geq 65$  years.
2. Patients with diabetes, COPD, CKD, heart disease, or immunocompromise<sup>119</sup>

#### Prevention Strategies

1. Smoking cessation
2. Indoor air pollution reduction (e.g., improved stoves)
3. Diabetes and NCD control
4. Oral hygiene, nutrition, and vaccination awareness<sup>120</sup>

## Clinical Algorithm (Text-Based Version)

### CAP Diagnostic and Treatment Flow

#### Step 1: Identify Clinical Signs

- Cough ± sputum, dyspnea, pleuritic chest pain, fever, crepitations

#### Step 2: Baseline Investigations

- a. Chest X-ray
- b. CBC, CRP ± PCT
- c. Sputum and blood cultures (before antibiotics, especially in patients who need hospitalization)

#### Step 3: Severity Stratification (CURB-65)

- a. Score 0–1: Outpatient care
- b. Score 2: Admit to ward
- c. Score ≥3: Admit + consider ICU

#### Step 4: Empirical Antibiotics (Risk-Adjusted)

- a. Outpatient: Amox-Clav or Doxycycline
- b. Ward: Ceftriaxone + Azithromycin
- c. ICU: Pip-Tazo/Cefepime + Azithromycin ± Vancomycin

#### Step 5: Reassess at 48–72 Hours

- a. If afebrile + improving → Oral switch
- b. If worsening → Evaluate for DRPs, imaging, culture results

#### Step 6:

- Stop antibiotics by Day 5–7 (if stable)

#### Step 7:

- a. Plan Discharge once stable, and OPD Follow-up
- b. Vaccination, prevention, warning signs, follow-up date

## Health System Implementation Priorities

### Electronic Medical Records (EMR) Integration

1. Embed CAP care pathways, scoring tools (CURB-65), antibiograms, and order sets
2. Include vaccination status tracking and oral switch alerts<sup>121</sup>

Performance Indicators for National Roll-Out: Hospitals and regional programs should report:

1. % of CAP cases with pre-antibiotic cultures sent
2. % with CURB-65 documentation
3. % on guideline-concordant empiric therapy
4. % transitioned to oral antibiotics by Day 3
5. 30-day readmission and CAP-related mortality<sup>122</sup>

## Training & Dissemination

1. Develop bilingual (English/Urdu) formats for physicians, nurses, pharmacists, and Lady Health Workers
2. Use video modules, app-based tools, and CME-certified webinars<sup>123</sup>

## Linkages with Surveillance and Reporting

Align CAP care with:

1. National AMR Surveillance Network
2. EPI adult vaccine records
3. Hospital pneumonia dashboards for antimicrobial use, diagnostics, and outcome tracking<sup>124</sup>
4. National Institute of Health. CAP Reporting and Surveillance Dashboard Framework. 2024.

## PICO Questions

### PICO 1

**Question:** In adults with CAP, is azithromycin more effective than amoxicillin–clavulanate in achieving clinical recovery within 7 days?

**Answer:**

Amoxicillin–clavulanate is the preferred empirical therapy for mild to moderate CAP in Pakistan, as it offers reliable coverage against *Streptococcus pneumoniae* and *Haemophilus influenzae*, which are the most commonly isolated organisms in local settings.<sup>41,125</sup>

Azithromycin, while effective against atypical pathogens such as *Mycoplasma pneumoniae* and *Legionella*, is increasingly limited by macrolide resistance. Local Pakistani antibiograms from Lahore and Karachi report macrolide resistance rates exceeding 30–35% among *S. pneumoniae* isolates.<sup>7,126</sup> Regional Indian data (ICS Guidelines 2012) also emphasize amoxicillin–clavulanate as first-line therapy for typical CAP presentations.<sup>24</sup> Global BTS 2023 guidelines recommend macrolides only when atypical pathogens are strongly suspected or as add-on therapy in moderate to severe CAP.<sup>23</sup>

**Recommendation:** Use amoxicillin–clavulanate as the empirical first line treatment in typical mild to moderate CAP; azithromycin should be reserved for suspected atypical pneumonia or combination therapy where warranted.<sup>23,24,125</sup>

### PICO 2

**Question:** In adults ≥65 years, does pneumococcal vaccination reduce the incidence of pneumonia compared to no vaccination?

**Answer:**

Yes. Multiple global and regional studies confirm that pneumococcal conjugate vaccines (PCVs) significantly reduce incidence of both invasive and non-invasive pneumococcal disease in the elderly.<sup>127</sup>

Data from Pakistan show very low vaccination uptake (14%) in high-risk adults, despite a high burden of vaccine-preventable CAP.<sup>128</sup>

A multicenter Indian trial demonstrated a 48% reduction in pneumonia hospitalization post-PCV13 implementation.<sup>129</sup>

Global ACIP guidelines (2023) recommend PCV20 for all adults  $\geq 65$  or those with comorbidities such as diabetes, CKD, or COPD.<sup>130</sup>

In the UAE and Saudi Arabia, national programs have integrated adult pneumococcal vaccination into primary care bundles, resulting in measurable reductions in disease burden.<sup>131,132</sup>

**Recommendation:** Strongly recommend PCV13/15/20 in all adults  $\geq 65$  and in younger adults with risk factors. Booster with PPSV23 may follow depending on regimen.<sup>68,73,128,129,133</sup>

### PICO 3

**Question:** In adults with CAP, is chest CT more accurate than point-of-care ultrasound (POCUS) for diagnosis?

**Answer:**

Chest CT is considered the gold standard for diagnosis of CAP, with sensitivity approaching 98% and excellent visualization of infiltrates, pleural effusions, and complications.<sup>134,135</sup>

However, its routine use is impractical in resource-limited settings like many

Pakistani hospitals due to cost and availability.<sup>136</sup>

POCUS offers a promising alternative. Studies from India and Middle East show that LUS has a sensitivity of 88–91% and specificity of 86–90%, making it highly useful for initial assessment and follow-up.<sup>137–139</sup>

In a 2021 Pakistani study, POCUS was successfully adopted in emergency departments for triaging suspected CAP patients, with diagnostic concordance exceeding 80% vs. CXR.<sup>140</sup>

Global BTS 2023 guidelines support LUS in settings where radiology access is limited.<sup>23</sup>

**Recommendation:** A gradual roll out for the use of LUS/POCUS in rural or low resource settings, after addressing appropriate training and basic machine cost; reserve CT for complicated, non-resolving, or unclear cases.<sup>23,134,138,139</sup>

### PICO 4

**Question:** In hospitalized adults with severe CAP, does early ICU admission reduce mortality compared to ward management?

**Answer:**

Yes. International studies have shown that early ICU transfer (within 6 hours of triage) is associated with improved survival and shorter LOS, particularly in patients with CURB-65  $\geq 3$ , hypotension, or multi-lobe infiltrates.<sup>141</sup> In Pakistan, delayed ICU admission due to bed shortages is a common issue, with mortality in delayed-admission groups reported at 2–3 times higher in retrospective reviews from tertiary centers in Karachi and Rawalpindi.<sup>142</sup> The Indian RESP-NET and Sri Lankan critical care networks also advocate for severity score-based early ICU triage, which has improved 30-day mortality by ~15–20% in their populations.<sup>28,143</sup>

**Recommendation:** Use CURB-65 or PSI to triage early. Immediate ICU transfer should be considered in any patient with hypotension, confusion, or respiratory failure.<sup>15,143,144</sup>

## PICO 5

**Question:** In adults with CAP, does levofloxacin lead to faster symptom resolution compared to amoxicillin–clavulanate?

### Answer:

Levofloxacin is a broad-spectrum fluoroquinolone with high tissue penetration and coverage for both typical and atypical pathogens. Meta-analyses suggest quicker resolution of fever and cough (1–2 days faster) compared to beta-lactams.<sup>145</sup>

However, fluoroquinolone-associated risks include QT prolongation, *Clostridium difficile* infection, and tendon rupture—particularly in older adults.<sup>146,147</sup> In Pakistani settings, levofloxacin resistance is on the rise, particularly in *K.*

pneumoniae and *P. aeruginosa* strains isolated from post-COVID CAP patients.<sup>19</sup>

Indian and GCC guidelines recommend restricting fluoroquinolones to moderate/severe CAP, or when beta-lactams are contraindicated.<sup>24,133</sup>

**Recommendation:** Reserve levofloxacin for severe CAP, beta-lactam allergy, or confirmed atypical pathogens. Avoid indiscriminate first-line use.<sup>24,133,145,147</sup>

## PICO 6

**Question:** In patients with CAP and comorbid type 2 diabetes mellitus (T2DM), does early initiation of empirical antibiotics reduce complications compared to delayed therapy?

### Answer:

Yes. Patients with T2DM are at significantly increased risk for severe CAP, delayed resolution, and treatment failure, due to impaired neutrophil function and increased colonization with multidrug-resistant organisms (MDROs).<sup>148</sup> Multiple studies have shown higher ICU admission and mortality rates in diabetic patients with delayed therapy (>6 hours post-presentation).<sup>149,150</sup> Indian data (RESP-NET 2018) show that early antibiotic administration (<4 hours) in diabetics reduced complication rates by 30%.<sup>103</sup>

BTS 2023 and IDSA 2021 guidelines both advocate for early empiric antibiotic initiation, particularly in high-risk groups like diabetics, elderly, or immunocompromised patients.<sup>23,48</sup>

**Recommendation:** In patients with T2DM and suspected CAP, empiric antibiotics should be initiated within 3–4 hours of diagnosis or triage, even while awaiting labs.<sup>23,48,148,150</sup>

In general, this practice will benefit all subsets of patients.

## PICO 7

**Question:** In adults with moderate CAP, does switching from intravenous to oral antibiotics within 48–72 hours result in similar outcomes to prolonged IV therapy?

### Answer:

Yes. International trials (e.g., STEP, 2020) show that early IV-to-oral switch at 48–72 hours in stable patients (afebrile, normal vitals, oral intake) leads to equivalent cure rates, reduced hospital stays, and lower costs.<sup>151,152</sup>

In Pakistani settings, limited prospective data support this transition model in tertiary care hospitals with outcomes comparable to global data.<sup>153</sup>

Regional implementation in UAE and Thailand has reduced average length of stay by 1.5–2 days per case.<sup>90,133</sup>

BTS 2023 and WHO Southeast Asia guidelines endorse early switch as a safe, evidence-based standard.<sup>23,77</sup>

**Recommendation:** IV-to-oral switch should be considered in all clinically stable CAP patients within 48–72 hours unless complications arise.<sup>23,55,77,90</sup>

### PICO 8

**Question:** In outpatient management of CAP, does monotherapy with a beta-lactam result in similar clinical outcomes compared to combination therapy with beta-lactam plus macrolide?

**Answer:**

Yes, for low-risk patients. The CAP-OPT trial and BTS 2023 data suggest that in outpatient, otherwise healthy adults, beta-lactam monotherapy (e.g., amoxicillin–clavulanate) achieves similar resolution rates compared to combination therapy.<sup>23,154</sup>

Local Pakistani data show low prevalence of atypical organisms in community CAP isolates (~8%), limiting the added value of macrolides in most cases.<sup>16</sup> Whether this reflects a true divergence from the norm, or it is a result of unavailable widespread adherence to or access to the diagnostics / cultures, is a debatable query. However, regional surveillance in India and Bangladesh indicate higher atypical pathogen frequency (~12–18%), where combination therapy might be more useful.<sup>155,156</sup>

IDSA 2021 recommends monotherapy for low-risk patients, reserving dual therapy for those with comorbidities or where atypicals are suspected.<sup>48</sup>

**Recommendation:** In young, immunocompetent adults with mild CAP and no comorbidities, beta-lactam monotherapy is sufficient. Use dual therapy only in moderate-risk patients or atypical suspicion.<sup>23,48,154–156</sup>

### PICO 9

**Question:** In adult patients with CAP, is CRP a reliable tool to monitor antibiotic response compared to clinical criteria alone?

**Answer:**

Yes, in moderate to severe CAP. CRP levels fall rapidly with effective therapy and may serve as an objective adjunct to clinical evaluation.<sup>157</sup>

A study in Lahore hospitals demonstrated that CRP levels ≤50 mg/L by Day 3 were associated with treatment success and early discharge.<sup>8</sup>

International guidelines (NICE, IDSA) support using CRP as a guide to assess response and to reduce unnecessary duration of antibiotics.<sup>48,158</sup>

CRP testing is cost-effective and available in most urban tertiary centers across Pakistan.<sup>159</sup>

**Recommendation:** CRP can be used alongside clinical signs to monitor recovery and guide oral switch or discharge decisions in hospitalized patients.<sup>48,157–159</sup>

### PICO 10

**Question:** In hospitalized patients with CAP, does a total antibiotic duration of 5 days lead to similar outcomes as 7–10 days?

**Answer:**

Yes, if the patient is clinically stable by Day 5. A recent systematic review of seven RCTs shows that 5-day antibiotic courses are as effective as longer regimens, with fewer adverse events and lower resistance risk.<sup>160</sup>

Pakistan-based audits noted high rates of unnecessary extension of therapy beyond Day 7, especially in low-risk CAP.<sup>161</sup>

Indian CAP audits similarly recommend 5-day regimens for low-to-moderate CAP with early switch to oral therapy.<sup>162</sup>

BTS 2023 and WHO SEARO both endorse short-course therapy where resolution is evident.<sup>23,77</sup>

**Recommendation:** Total duration of antibiotics should not exceed 5–7 days in uncomplicated CAP unless clinically indicated.<sup>23,48,77,162</sup>

### PICO 11

**Question:** In hospitalized patients with CAP, does obtaining sputum and blood cultures before initiating antibiotics improve pathogen-directed therapy outcomes compared to empirical treatment alone?

**Answer:**

Yes. Blood and sputum cultures obtained before the first dose of antibiotics increase the likelihood of identifying the causative organism, enabling more precise and de-escalated therapy.<sup>163,164</sup>

In Pakistani tertiary hospitals, culture positivity rates vary from 18–34%, with higher yield when samples are obtained prior to antibiotic administration.<sup>16</sup>

A multicenter Indian study showed that pre-antibiotic cultures improved antibiotic stewardship by reducing broad-spectrum use in 22% of cases.<sup>114</sup>

BTS 2023 and IDSA 2021 recommend collecting cultures in all hospitalized or high-risk CAP cases, even if empirical treatment must begin concurrently.<sup>23,48</sup> Delays in culture collection post-antibiotics lead to poor yield, resulting in unnecessarily prolonged empirical regimens and higher resistance risk.<sup>163</sup>

**Recommendation:** Sputum and blood cultures should be obtained before the first antibiotic dose in all moderate to severe, hospitalized CAP cases or when MDR organisms are suspected.<sup>23,48,163,164</sup>

### PICO 12

**Question:** In patients with CAP and COPD, does addition of corticosteroids to standard therapy reduce time to clinical stability compared to antibiotics alone?

**Answer:**

Yes, but selectively. Corticosteroids can reduce inflammation and hasten clinical recovery in moderate to severe CAP with COPD exacerbation, but must be used cautiously.<sup>165,166</sup>

A trial in Karachi (N=508) demonstrated that short-course prednisone (40 mg/day × 5 days) reduced hospital stay and oxygen requirement in COPD-CAP patients by ~1.5 days.<sup>167</sup>

The Indian Chest Society and Middle Eastern consensus guidelines recommend adjunct steroids in CAP with bronchospasm or high CRP (>150 mg/L).<sup>24,133</sup> However, adverse events such as hyperglycemia and secondary infections necessitate close monitoring.<sup>167</sup>

BTS 2023 recommends against routine steroid use unless there is another compelling indication (e.g., adrenal insufficiency, severe inflammatory phenotype).<sup>23</sup>

**Recommendation:** Use corticosteroids only in severe CAP with COPD or strong inflammatory markers and monitor closely for complications.<sup>23,133,165–167</sup>

### PICO 13

**Question:** In adults with CAP, is the use of CURB-65 superior to PSI for predicting 30-day mortality and guiding site-of-care decisions?

**Answer:**

Both scores are validated, but CURB-65 is simpler and easier to apply in resource-limited settings such as Pakistan, with similar prognostic accuracy for 30-day mortality.<sup>30,168</sup>

Local data from Lahore show CURB-65 had AUC = 0.82 for mortality prediction, comparable to PSI (AUC = 0.84), but required fewer clinical/lab inputs.<sup>8</sup>

The BTS 2023 and WHO SEARO guidelines recommend CURB-65 for primary triage and site-of-care decisions due to its simplicity and scalability.<sup>23,77,169</sup>

In regional data from India and Bangladesh, CURB-65 stratification was associated with more appropriate hospital admissions and lower ICU delays.<sup>170,168</sup>

**Recommendation:** Use CURB-65 routinely in all adults with suspected CAP to predict severity and aid in decision-making for admission or discharge.<sup>23,28,32,34,168,169</sup>

#### PICO 14

**Question:** In patients with CAP, does lack of adherence to national guidelines increase length of hospital stay or antibiotic overuse?

**Answer:**

Yes. Non-adherence to clinical pathways results in inappropriate broad-spectrum antibiotic use, prolonged IV therapy, and longer hospital stay.<sup>171,172</sup> A nation-wide study across ten cities of Pakistan showed low physician awareness and inconsistent recommendations as the contributing factors for non-adherence to the CAP guidelines.<sup>26</sup>

Global WHO data suggest that lack of protocol adherence increases resistance pressure and costs of care by up to 40% in LMICs.<sup>110</sup>

UAE and Sri Lankan hospitals implementing digital protocols have demonstrated reduced median hospital stay by 1.2 days and better rational drug use metrics.<sup>173,174</sup>

**Recommendation:** Strict adherence to CAP national guidelines and electronic clinical pathways must be enforced to improve outcomes and curb AMR.<sup>171–174</sup>

#### PICO 15

**Question:** In patients with CAP during influenza season, does empiric addition of oseltamivir improve clinical outcomes compared to antibiotics alone?

**Answer:**

Yes, during peak influenza circulation, co-infection with influenza and bacterial pathogens increases severity, ICU admission, and mortality.<sup>175</sup>

In Pakistan, surveillance during 2018–2022 showed 8–12% viral-bacterial coinfection in hospitalized CAP cases during winter.<sup>176</sup>

A Karachi-based study showed that early empiric oseltamivir (within 48h) in high-risk patients led to improved recovery rates and reduced duration of hospitalization by ~2 days.<sup>177</sup>

IDSA, CDC, and WHO recommend empiric oseltamivir during known community outbreaks or in severe CAP when influenza cannot be ruled out.<sup>48,178,179</sup>

**Recommendation:** In peak influenza season, initiate empiric oseltamivir in hospitalized patients with CAP and risk factors, even while awaiting PCR results.<sup>48,176–179</sup>

#### PICO 16

**Question:** In adult patients with CAP, does the use of a local antibiogram improve empirical antibiotic appropriateness compared to relying on international guidelines alone?

**Answer:**

Yes. Empirical treatment based solely on international recommendations may not address local resistance patterns, particularly in regions with high antimicrobial resistance (AMR) like Pakistan.<sup>7</sup>

Recent antibiograms from tertiary hospitals in Lahore, Karachi, and Islamabad show resistance to macrolides exceeding 30%, and increasing fluoroquinolone resistance among *S. pneumoniae* and *K. pneumoniae*.<sup>19</sup>

A 2022 national survey under NIH Pakistan found guideline-discordant empiric therapy in 41% of cases when local antibiograms were not used.<sup>180</sup>

The BTS 2023 and WHO GLASS protocols advocate integrating local surveillance data to inform empiric treatment, especially in LMICs.<sup>23,110</sup>

**Recommendation:** All empiric therapy should be guided by updated local antibiograms, and guideline panels must revise national protocols accordingly.<sup>7,23,110,180</sup>

### PICO 17

**Question:** In patients with CAP and underlying heart failure (HF), does early use of diuretics alongside antibiotics improve oxygenation and hospital stay compared to antibiotics alone?

**Answer:**

Yes. In CAP patients with HF, fluid overload can mask or worsen pulmonary findings. Early diuresis improves oxygenation, reduces need for high-flow oxygen, and shortens stay.<sup>181</sup>

Pakistani studies show that cardiopulmonary overlap in CAP+HF is often underrecognized, contributing to delayed response to antibiotics alone.<sup>182</sup>

A 2019 Indian multicenter trial showed early furosemide use improved PaO<sub>2</sub>/FiO<sub>2</sub> ratios and decreased need for mechanical ventilation by 28%.<sup>183</sup> BTS 2023<sup>2023</sup> emphasizes individualizing fluid balance in patients with CAP and preexisting HF.<sup>23</sup>

**Recommendation:** Screen for HF in all CAP admissions; start early diuretics in volume-overloaded patients with preserved perfusion.<sup>23,181–183</sup>

### PICO 18

**Question:** In adults with CAP caused by multidrug-resistant organisms (MDROs), does rapid diagnostic testing improve clinical outcomes compared to conventional cultures?

**Answer:**

Yes. Rapid molecular diagnostic tests (e.g., multiplex PCR, LAMP assays) detect pathogens and resistance markers within hours, enabling targeted therapy.<sup>184,185</sup> A study from Aga Khan University Hospital reported that BioFire® respiratory panel use reduced time to de-escalation by 2.6 days and improved clinical outcomes.<sup>186</sup>

Indian and Middle Eastern hospitals have adopted these technologies with significant impact on antibiotic stewardship and cost containment.<sup>187–189</sup> WHO and BTS 2023 support rapid testing, especially in ICU CAP or where MDRO suspicion is high.<sup>23,169</sup>

**Recommendation:** Where available, molecular diagnostic tools should supplement cultures for rapid pathogen identification in severe or MDRO suspected CAP.<sup>23,184,186–189</sup>

### PICO 19

**Question:** In hospitalized adults with CAP and altered mental status, does routine screening for aspiration pneumonia improve outcomes compared to no screening?

**Answer:**

Yes. Altered mental status (e.g., dementia, delirium, stroke) increases aspiration risk. Routine assessment (bedside swallow, chest imaging, pH studies) can detect aspiration early and guide therapy.<sup>190,191</sup>

A KPK-based study found that 26% of CAP cases in elderly with altered mental state were due to silent aspiration, requiring anaerobic coverage.<sup>23,192</sup>

BTS and Canadian guidelines advise considering aspiration when right lower lobe consolidation, poor oral hygiene, or swallowing dysfunction is present. Indian and UAE protocols recommend adding metronidazole or clindamycin in aspiration-suspected CAP.<sup>193,194</sup>

**Recommendation:** Routinely screen for aspiration in elderly or neurologically impaired CAP patients and adjust therapy accordingly.<sup>23,192–194</sup>

### PICO 20

**Question:** In community settings, does the implementation of pneumonia awareness and vaccination campaigns reduce incidence and severity of CAP compared to no intervention?

**Answer:**

Yes. Public education and vaccination outreach programs improve early care-seeking, reduce inappropriate antibiotic use, and increase immunization uptake.<sup>195,196</sup>

In a Karachi intervention, pneumonia awareness and PCV campaigns increased adult vaccination by 31% and reduced CAP hospitalization by 24% in 18 months.<sup>197</sup>

GAVI- and WHO-supported campaigns in South Asia (e.g., India, Nepal, Bangladesh) also demonstrated increased vaccine coverage and decreased CAP mortality.<sup>77,97,198</sup>

**Recommendation:** Community awareness, education, and vaccination drives should be integral to CAP control strategy in Pakistan.<sup>76,96,194–196</sup>

## Reference

1. World Health Organization. Global Health Estimates 2023. WHO; 2024. 2024 [cited 2025 Jul 31]. Available from: <https://www.who.int/data/gho/publications/world-healthstatistics/1000>
2. Peto L, Nadjm B, Horby P, Ngan TTD, van Doorn R, Van Kinh N, et al. The bacterial etiology of adult community-acquired pneumonia in Asia: A systematic review. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. Oxford University Press; 2014. 108; p. 326–37. Doi: <https://doi.org/10.1093/trstmh/tru05>
3. Iqbal N, Irfan M, Siddique F, Arshad V, Zubairi ABS. Factors predicting in-hospital mortality among patients admitted with community acquired pneumonia at a tertiary care hospital Karachi, Pakistan. *Clin Respir J*. 2020 Apr 1 [cited 2025 Jul 31];14(4):328–34. Doi: <https://doi.org/10.1111/crj.13137>
4. Integrated Disease Surveillance & Response (IDSR) Report, Center of Disease Control, National Institute of Health, Islamabad; Available from: [www.phb.nih.org.pk/](http://www.phb.nih.org.pk/)
5. Pakistan Air Quality Index (AQI) and Air Pollution information | IQAir. [cited 2025 Jul 31]. Available from: [https://www.iqair.com/pakistan?srsId=AfmBOoqmhjtxuzVy7zG0VebCHGzj8xTB8sqFRCLeh2qiFJwxEwNg\\_zld](https://www.iqair.com/pakistan?srsId=AfmBOoqmhjtxuzVy7zG0VebCHGzj8xTB8sqFRCLeh2qiFJwxEwNg_zld)
6. Arshad I, Khalid S, Khan S, Bashir S, Waseem H, Naveed M. Community acquired pneumonia and demographic factors: A cross-sectional study. *Journal of Fatima Jinnah Medical University*. 2019 Nov 16 [cited 2025 Jul 31];13(2):83–6. Available from: <https://www.fjmu.com/index.php/ojs/article/view/564>
7. Torumkuney D, Jamil B, Nizamuddin S, Van Hasselt J, Pirzada U, Manenzhe R. Country data on AMR in Pakistan in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicine and clinical outcome. *Journal of Antimicrobial Chemotherapy*. 2022 Sep 6 [cited 2025 Jul 31];77(1):i18–25. Doi: <https://dx.doi.org/10.1093/jac/dkac213>
8. Adnan M, Hashmat N, Rahat T, Burki A. Prognostic value of five serum markers predicting in-hospital mortality among adults with community acquired pneumonia. *The Journal of Infection in Developing Countries*. 2022 Jan 31 [cited 2025 Jul 31];16(01):166–72. Available from: <https://jidc.org/index.php/journal/article/view/14495>
9. PCS Guidelines: Guidelines for The Management of Community Acquired Pneumonia in Adults. 2020 [cited 2025 Jul 31]. Available from: <https://pakistanchestssociety.pk/pcsguidelines/>
10. Torumkuney D, Anwar S, Nizamuddin S, Malik N, Morrissey I. Results from the Survey of Antibiotic Resistance (SOAR) 2015–17 in Pakistan: Data based on CLSI, EUCAST (dosespecific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. *Journal of Antimicrobial Chemotherapy*. 2020 Apr 1;75:176–87. Doi: <https://doi.org/10.1093/jac/dkaa085>
11. Mao S, Wu L. Coinfection of viruses in children with community-acquired pneumonia. *BMC Pediatr*. 2024 Dec 1 [cited 2025 Jul 31];24(1):457. Doi: <https://doi.org/10.1186/s12887024-04939-0>
12. Nisar MI, Kerai S, Shahid S, Qazi MF, Rehman S, Aziz F, et al. Predictors of Respiratory Syncytial Virus, Influenza Virus, and Human Metapneumovirus Carriage in Children Under 5 Years With WHO-Defined Fast-Breathing Pneumonia in Pakistan. *Influenza Other Respir Viruses*. 2024 Apr 1;18(4). Doi: <https://doi.org/10.1111/irv.13285>
13. American Thoracic Society Clinical Practice Guidelines, Statements. 2021 [cited 2025 Jul 31]. Available from: <https://site.thoracic.org/clinicians-researchers/clinical-practiceguidelines-statements-reports>
14. Reports – DISTRICT HEALTH OFFICE. [cited 2025 Jul 31]. Available from: <https://dhoict.gov.pk/reports/>
15. Mansoor F, Akhtar A, Sikandar I, Qadeer A, Ali Z, Kaleem B. What Factors on Admission influence ICU Mortality in Adult Patients Admitted to the Intensive Care Unit with Severe Pneumonia? *Pak Armed Forces Med J*. 2016;66(4):548–52.
16. Rahil K, Fazila K. Bacterial Etiology of Adult Community-Acquired Pneumonia in Pakistan: A Systematic Review and Meta-Analysis. *Archives of community medicine and public health*. 2025 Jan 1 [cited 2025 Aug 1];11(1):001–7. Doi: <https://doi.org/10.17352/24555479.000215>

17. Razazi K, Mekontso Dessap A, Carteaux G, Jansen C, Decousser JW, de Prost N, et al. Frequency, associated factors and outcome of multi-drug-resistant intensive care unit-acquired pneumonia among patients colonized with extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae. *Ann Intensive Care*. 2017 Dec 1;7(1). Doi: <https://doi.org/10.1186/s13613-017-0283-4>
18. Khan ZA, Ali AS, Ahmed I, Farooqi J, Irfan M. Frequency of viral etiology in community-acquired pneumonia. *Monaldi Archives for Chest Disease*. 2025 Jan 17. Doi: <https://doi.org/10.4081/monaldi.2025.3161>
19. Bilal H, Khan MN, Rehman T, Hameed MF, Yang X. Antibiotic resistance in Pakistan: a systematic review of past decade. *BMC Infect Dis*. 2021 Dec 1 [cited 2025 Aug 1];21(1):1–19. Doi: <https://doi.org/10.1186/s12879-021-05906-1>
20. Saleem Z, Godman B, Azhar F, Kalungia AC, Fadare J, Opanga S, et al. Progress on the national action plan of Pakistan on antimicrobial resistance (AMR): a narrative review and the implications. *Expert Rev Anti Infect Ther*. 2022 Jan 2 [cited 2025 Aug 1];20(1):71–93. Doi: <https://doi.org/10.1080/14787210.2021.1935238>
21. Saleem Z, Hassali MA, Godman B, Hashmi FK, Saleem F. Antimicrobial prescribing and determinants of antimicrobial resistance: a qualitative study among physicians in Pakistan. *Int J Clin Pharm*. 2019 Oct 1 [cited 2025 Aug 1];41(5):1348–58. Doi: <https://doi.org/10.1007/s11096-019-00875-7>
22. Lim WS, Van Der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. *Thorax*. 2003 May 1 [cited 2025 Aug 1];58(5):377–82. Doi: <https://doi.org/10.1136/thorax.58.5.377>
23. Pneumonia Adults | British Thoracic Society | Better lung health for all. BTS Guidelines for the Management of Community Acquired Pneumonia. 2023 [cited 2025 Aug 2]. Available from: <https://www.brit-thoracic.org.uk/quality-improvement/guidelines/pneumoniaadults/>
24. Sharma BB, Singh V. Indian pneumonia guidelines. *Lung India*. 2012 Oct [cited 2025 Aug 1];29(4):307–8. Available from: [https://journals.lww.com/lungindia/fulltext/2012/29040/indian\\_pneumonia\\_guidelines.1.aspx](https://journals.lww.com/lungindia/fulltext/2012/29040/indian_pneumonia_guidelines.1.aspx)
25. Francis NA, Cals JW, Butler CC, Hood K, Verheij T, Little P, et al. Severity assessment for lower respiratory tract infections: Potential use and validity of the CRB-65 in primary care. *Primary Care Respiratory Journal*. 2012 Mar [cited 2025 Aug 1];21(1):65–70. Doi: <https://doi.org/10.4104/pcrj.2011.00083>
26. Ullah S, Khan J, Khan A, Hashemy I. Assessing decision of inpatient or outpatient care in community acquired pneumonia: APT care study. 2017;67(3):380–5. PMID: 28303986.
27. Fine MJ, Hanusa BH, Lave JR, Singer DE, Stone RA, Weissfeld LA, et al. Comparison of a disease-specific and a generic severity of illness measure for patients with community-acquired pneumonia. *J Gen Intern Med*. 1995 Jul. [cited 2025 Aug 1];10(7):359–68. Doi: <https://doi.org/10.1007/bf02599830>
28. Reddy SBM, Gitte SY, Satpute SA, Patil S. Study of Pneumonia Severity Index and Curb-65 In Community Acquired Pneumonia in Industrial Set-Up. *Journal of Population Therapeutics and Clinical Pharmacology*. 2024 Sep 23 [cited 2025 Aug 1];31(9):1636–45. Doi: <https://doi.org/10.53555/gtfpk192>
29. Pakpahan FS, Bihar S, Syarani F, Eyaner PC. Accuracy Between CURB-65 Score and PSI in Determining the Prognosis of Community-Acquired Pneumonia Patients at H. Adam Malik General Hospital, Medan. *Respiratory Science*. 2021 Jun 23;1(3):174–81. Doi: <https://doi.org/10.36497/respirsci.v1i3.25>
30. Barlas RS, Clark AB, Loke YK, Kwok CS, Angus DC, Uranga A, et al. Comparison of the prognostic performance of the CURB-65 and a modified version of the pneumonia severity index designed to identify high-risk patients using the International Community-Acquired Pneumonia Collaboration Cohort. *Respir Med*. 2022 Aug 1;200. Doi: <https://doi.org/10.1016/j.rmed.2022.106884>

- 31.**Babu A, Jose N, Jose J. A Prospective Observational Study to Evaluate Severity Assessment Scores in Community-acquired Pneumonia for Adult Patients. *Indian Journal of Respiratory Care*. 2022 Dec 2 [cited 2025 Aug 1];6(2):820–3. Available from: <https://link.gale.com/apps/doc/A565960528/AONE?>
- 32.**Ronan D, Nathwani D, Davey P, Barlow G. Predicting mortality in patients with community-acquired pneumonia and low CURB-65 scores. *European Journal of Clinical Microbiology and Infectious Diseases*. 2010 [cited 2025 Aug 1];29(9):1117–24. Doi: <https://doi.org/10.1007/s10096-010-0970-7>
- 33.**Moon JY, El Labban M, Gajic O, Odeyemi Y. Strategies for preventing and reducing the impact of acute respiratory failure from pneumonia. *Expert Rev Respir Med*. 2025 Mar 4 [cited 2025 Aug 1];19(3):205–21. Doi: <https://doi.org/10.1080/17476348.2025.2464880>
- 34.**Kumari N, Saifullah N, Jafri S, Ahmed A, Jawad N, Ahmed N. Comparison of NEWS2 and PSI as mortality predictors in patients with community-acquired pneumonia. *J Pak Med Assoc*. 2024 Jun 1;74(6):1156–9. Doi: <https://doi.org/10.47391/jpma.10031>
- 35.**Ullah AR, Masood A, Amin S, Ali I. Predictive factors and outcomes of severe community-acquired pneumonia in patients with respiratory failure. *Pak J Med Sci*. 2022 Mar 1 [cited 2025 Aug 1];38(4Part-II):1031. Doi: <https://doi.org/10.12669/pjms.38.4.5312>
- 36.**Munian D, Roy O, Poddar S, Hazra A, Ray S. A Prospective Cohort Study on Spectrum of Community-Acquired Late Onset Neonatal Pneumonia: An Eye Opener for Neonatal Care. *Journal of Neonatology*. 2023 Dec 1 [cited 2025 Aug 1];37(4):317–24. Doi: <http://dx.doi.org/10.1177/09732179231172275>
- 37.**Habib SS, Jamal WZ, Zaidi SMA, Siddiqui JUR, Khan HM, Creswell J, et al. Barriers to Access of Healthcare Services for Rural Women—Applying Gender Lens on TB in a Rural District of Sindh, Pakistan. *International Journal of Environmental Research and Public Health* 2021, Vol 18, Page 10102. 2021 Sep 26 [cited 2025 Aug 6];18(19):10102. <https://doi.org/10.3390/ijerph181910102>
- 38.**Service Availability and Readiness Assessment Survey in The Islamabad Capital Territory Islamic Republic of Pakistan Consolidated Report. Available from: <https://www.who.int/data/data-collection-tools/service-availability-and-readinessassessment>
- 39.**Altaf U, Saleem Z, Akhtar MF, Altowayan WM, Alqasoumi AA, Alshammari MS, et al. Using Culture Sensitivity Reports to Optimize Antimicrobial Therapy: Findings and Implications of Antimicrobial Stewardship Activity in a Hospital in Pakistan. *Medicina-lithuania*. 2023 Jul 2 [cited 2025 Aug 1];59(7):1237–1237. Doi: <https://doi.org/10.3390/medicina59071237>
- 40.**Zhang D, Yang D, Makam AN. Utility of Blood Cultures in Pneumonia. *Am J Med*. 2019 Oct 1 [cited 2025 Aug 1];132(10):1233. Doi: <https://doi.org/10.1016/j.amjmed.2019.03.025>
- 41.**Zafar A, Salahuddin A, Haque NS, Waheed AS, Khan S. Atypical pathogens causing community-acquired pneumonia in adults. [Vol. 62, JPMA. *The Journal of the Pakistan Medical Association*. 2012. PMID: 23866508.
- 42.**Ayaz N, Ilyas A, Iqbal A, Ullah I, Khan I, Mehmood I. Evaluating the Diagnostic Accuracy of C-Reactive Protein in Diagnosing Pneumonia in Children Using Blood Culture as the Gold Standard: C-Reactive Protein in Diagnosing Pneumonia. *Pakistan Journal of Health Sciences*. 2024 Aug 31 [cited 2025 Aug 1];5(08):93–7. Doi: <https://doi.org/10.54393/pjhs.v5i08.1822>
- 43.**Kwa ALH, Aninda Sidharta BR, Son DN, Zirpe K, Periyasamy P, Plongla R, et al. Clinical utility of procalcitonin in implementation of procalcitonin-guided antibiotic stewardship in the South-East Asia and India: evidence and consensus-based recommendations. *Expert Rev Anti Infect Ther*. 2024;22(1–3):45–58. Doi: <https://doi.org/10.1080/14787210.2023.2296066>
- 44.**Younus S, Maqsood H, Sattar A, Younas A, Shakeel HA. A novel chest CT severity score in COVID-19 and its correlation with severity and prognosis of the lung disease: A retrospective cohort study. *Annals of Medicine and Surgery*. 2022 Oct 1 [cited 2025 Aug 1];82:104692. Doi: <https://doi.org/10.1016/j.amsu.2022.104692>
- 45.**Qu, JX., Gu, L., Pu, ZH. et al. Viral etiology of community-acquired pneumonia among adolescents and adults with mild or moderate severity and its relation to age and severity.

2015. *BMC Infect Dis* 15, 89. Doi: <https://doi.org/10.1186/s12879-015-0808-0>
46. Pakistan Chest Society Guidelines for The Management of Community Acquired Pneumonia in Adults. 2015. Available from: [www.pakistanchestociety.pk/79\\_archives](http://www.pakistanchestociety.pk/79_archives)
47. Altaf U, Saleem Z, Furqan Akhtar M, Altowayan WM, Alqasoumi AA, Alshammari MS, et al. Using culture sensitivity reports to optimize antimicrobial therapy: findings and implications of antimicrobial stewardship activity in a hospital in Pakistan. *mdpi.com*. 2023 [cited 2025 Aug 2];59:1237. Doi: <https://doi.org/10.3390/medicina59071237>
48. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. ATS/IDSA Guidelines for Diagnosis and treatment of adults with community-acquired pneumonia. *Am J Respir Crit Care Med*. 2019 Oct 1 [cited 2025 Aug 2];200(7):45–67. Doi: <https://doi.org/10.1164/rccm.201908-1581st>
49. Khattak M, Farooq M, Khurram Shehzad Kazmi S, Saeed M, Usman M, Shuaib M. Pakistan Journal of Chest Medicine Official journal of Pakistan Chest Society. Correlation Between Chest Radiographic Findings, Sputum Bacterial Load, and Treatment Outcomes in Extensively Drug-resistant Tuberculosis Patients. *Pak J Chest Med*. 2022 Sep 2 [cited 2025 Aug 6];28(3):371-7. Available from: <https://pjcm.net/index.php/pjcm/article/view/863>
50. Khan M, Khan S, Basharat S. Gaps and Barriers to the Implementation of Antimicrobial Stewardship Programmes in Hospitals of Pakistan. Vol. 35, *Journal of the College of Physicians and Surgeons Pakistan*. College of Physicians and Surgeons Pakistan; 2025. p. 122–4. Doi: <https://doi.org/10.29271/jcpsp.2025.01.122>
51. Kaur J, Singh H, Sethi T. Emerging trends in antimicrobial resistance in bloodstream infections: multicentric longitudinal study in India (2017–2022). *The Lancet Regional Health - Southeast Asia*. 2024 Jul 1 [cited 2025 Aug 2];26:100412. Doi: <https://doi.org/10.1016/j.lansea.2024.100412>
52. Medrano PG, Weerasinghe N, Nagahawatte A, Vanderburg S, Park LP, Wijayarathne GB, et al. Prevalence and predictors of antibiotic prescription among patients hospitalized with viral lower respiratory tract infections in Southern Province, Sri Lanka. *PLoS One*. 2024 Jun 1;19(6 June). Doi: <https://doi.org/10.1371/journal.pone.0304690>
53. Anum Ashraf D. Comparative Efficacy of Amoxicillin Vs. Azithromycin in The Treatment of Pediatric Pneumonia. *Journal of Population Therapeutics & Clinical Pharmacology*. 2024 Nov 28;4028–33. Doi: <https://doi.org/10.53555/jptcp.v29i04.6653>
54. Khan MA, Ali SI, Kashif SS, Zafar F, Ali H, Fatima R, et al. Profile and management of community acquired pneumonia in a tertiary care hospital in Karachi. *International Journal of Medicine and Medical Sciences*. 2018 Feb 28 [cited 2025 Aug 2];10(2):31–5. Doi: <https://doi.org/10.5897/IJMMS2017.1342>
55. Deshpande A, Klompas M, Guo N, Imrey PB, Pallotta AM, Higgins T, et al. Intravenous to Oral Antibiotic Switch Therapy among Patients Hospitalized with Community-Acquired Pneumonia. *Clinical Infectious Diseases*. 2023 Jul 15 [cited 2025 Aug 2];77(2):174–85. Doi: <https://doi.org/10.1093/cid/ciad196>
56. Macdonald C, Jayathissa S, Leadbetter M. Is post-pneumonia chest X-ray for lung malignancy useful? Results of an audit of current practice. *Intern Med J*. 2015 Mar 1 [cited 2025 Aug 2];45(3):329–34. Doi: <https://doi.org/10.1111/imj.12699>
57. Sumreen A, Asmat K, Victor G, Sivarajan Froelicher E. Effectiveness of Discharge Education on 30-Day Readmission in Patients with Heart Failure: A Systematic Review and Meta-Analysis. *Journal of Health, Wellness and Community Research*. 2025 Apr 15 [cited 2025 Aug 2];e90–e90. Doi: <https://doi.org/10.61919/spg5xw45>
58. Sousa D, Justo I, Domínguez A, ... AMCM, 2013 undefined. Community-acquired pneumonia in immunocompromised older patients: incidence, causative organisms, and outcome. ElsevierD Sousa, I Justo, A Domínguez, A Manzur, C Izquierdo, L Ruiz, M Nebot, JM Bayas *Clinical Microbiology and Infection*, 2013, Elsevier. [cited 2025 Aug 2]; 19(2):187–92. Doi: <https://doi.org/10.1111/j.1469-0691.2012.03765.x>
59. Cilloniz C, Ceccato A, San Jose A, Torres A. Clinical management of community acquired pneumonia in the elderly patient. *Taylor & Francis*. 2016 Nov 1 [cited 2025 Aug 2];10(11):1211–20. Doi: <https://doi.org/10.1080/17476348.2016.1240037>

60. Kolditz M, International SEDÄ, 2017 undefined. Community-acquired pneumonia in adults. *Dtsch Arztebl Int.* 2017 Dec 8; [cited 2025 Aug 2]; 114(49):838-848. Doi: <https://doi.org/10.3238/arztebl.2017.0838>
61. Sarwar MR, Dar AR, Mahar SY, Riaz T, Danish U, Iftikhar S. Assessment of prescribing potentially inappropriate medications listed in Beer's criteria and its association with the unplanned hospitalization: a cross-sectional study in Lahore, Pakistan. *Clin Interv Aging.* 2018 [cited 2025 Aug 2]; 13:1485. Doi: <https://doi.org/10.2147/cia.s173942>
62. Jabbar R, Saeed M, Rasheed F, Iram S, Imran AA, Saeed S Ahmed M. Pathogens Causing Pneumonia Among Cancer Patients. Vol. 12, *Ann. Pak. Inst. Med. Sci.* 2016. [cited 2025 Aug 2]; 12(3):191-195. Available from: [https://apims.net/apims\\_old/Volumes/Vol12-4/Pathogens%20Causing%20Pneumonia%20Among%20Cancer%20Patients.pdf](https://apims.net/apims_old/Volumes/Vol12-4/Pathogens%20Causing%20Pneumonia%20Among%20Cancer%20Patients.pdf)
63. Grover SB, Grover H, Antil N, Patra S, Sen MK, Nair D. Imaging Approach to Pulmonary Infections in the Immunocompromised Patient. Vol. 32, *Indian Journal of Radiology, and Imaging.* Georg Thieme Verlag; 2022. [cited 2025 Aug 2]; 32(1):81-112. Doi: <https://doi.org/10.1055/s-0042-1743418>
64. Jadoon H, Sarwar I, Fawad A, Rehman S, Noor S, Bibi M. FETO-MATERNAL OUTCOMES OF MATERNAL SEPSIS: A SNAPSHOT OF THE ILLNESS. *Journal of Ayub Medical College.* 2023 Jul 1; [cited 2025 Aug 2]; 35(3):419-23. <https://doi.org/10.55519/jamc-03-12121>
65. AlJohi A, Alohalı A, Alsaeed S, Sakkijah HM, Obeid DA. Outcome of pregnant women admitted to critical care unit with confirmed severe COVID-19: A center experience. *Saudi Med J.* 2024 Apr 1 [cited 2025 Aug 3]; 45(4):379. Doi: <https://doi.org/10.15537/smj.2024.45.4.20240022>
66. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH, Marrie TJ, et al. Summary of Canadian Guidelines for the Initial Management of Community-acquired Pneumonia: An evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. *The Canadian Journal of Infectious Diseases.* 2000 [cited 2025 Aug 3]; 11(5):237. Doi: <https://doi.org/10.1155/2000/457147>
67. Ahmed I, Salman S, Musharraf MU, Riaz A, Baig AM, Umer A, et al. GUIDELINES FOR MANAGEMENT OF TYPE 2 DIABETES MELLITUS AND CARDIOMETABOLIC, Pakistan Endocrine Society (PES) SYNDROME. *Journal of Pakistan Medical Association.* 2023 [cited 2025 Aug 3]; 73(5):1-52. Available from: [https://jpma.org.pk/index.php/public\\_html/issue/view/46/1](https://jpma.org.pk/index.php/public_html/issue/view/46/1)
68. Kitchlew R, Latif S, Iqbal J, Saif S. Vaccination Status, Knowledge, Attitude and Perceptions of Vaccination against Influenza and Pneumococcal Pneumonia in Diabetic Population of Lahore, Pakistan. *Pakistan Journal of Public Health.* 2022 Dec 30 [cited 2025 Aug 3]; 12(4):188-93. Doi: <https://doi.org/10.32413/pjph.v12i4.1130>
69. Ghit A. Pneumococcal vaccination in diabetic patients: review from clinical practice. *Egypt J Intern Med.* 2023 Feb 27 [cited 2025 Aug 3]; 35(16). Doi: <https://doi.org/10.1186/s43162023-00202-7>
70. Bhattacharyya A, Shahabu ddin SM. Adult vaccination in India: A rapid review of current status & implementation challenges. *Indian J Med Res.* 2024 Sep 1 [cited 2025 Aug 3]; 160(3-4):279. Doi: [https://doi.org/10.25259/ijmr\\_1521\\_2024](https://doi.org/10.25259/ijmr_1521_2024)
71. Gamage A, Abeysinghe N, Kapuge Y. Country Case Study: Lessons Learned from Sri Lanka's Experience Transitioning from Gavi Support. 2021 Oct. Available from: <https://www.linkedimmunisation.org/resources/country-case-study-lessons-learned-from-sri-lankas-experience-transitioning-from-gavi-support/>
72. Koksai I, Al Awaidy S, Assiri AM, Ozudogru O, Khalaf M, Yeşiloğlu C, et al. Adult vaccination in three Eastern Mediterranean countries: current status, challenges, and the way forward. *Expert Rev Vaccines.* 2024 [cited 2025 Aug 3]; 23(1):1068-84. Doi: <https://doi.org/10.1080/14760584.2024.2428806>
73. Jamil B, Ahmed R, Bashir U, Luxmi S, Kulsoom S, Ashraf S, et al. Consensus statements for influenza awareness, prevention, and vaccination in Pakistan. *J Infect Dev Ctries.* 2024 Apr 1 [cited 2025 Aug 3]; 18(4):609-17. Doi: <https://doi.org/10.3855/jidc.18064>
74. Umbreen G, Rehman A, Avais M, Jabeen C, Sadiq S, Maqsood R, et al. Knowledge, Attitude,

- Practice and Barriers Associated with Influenza Vaccination among Health Care Professionals Working at Tertiary Care Hospitals in Lahore, Pakistan: A Multicenter Analytical Cross-Sectional Study. *Vaccines (Basel)*. 2023 Jan 1 [cited 2025 Aug 3];11(1). Doi: <https://doi.org/10.3390/vaccines11010136>
75. Hassan MZ, Haider S, Aleem MA, Islam MA, Shuvo TA, Bhuiya S, et al. Addressing influenza in Bangladesh: closing evidence and policy gaps with strategic interventions. *The Lancet Regional Health - Southeast Asia*. 2025 Jun 1 [cited 2025 Aug 3];37:100592. Doi: <https://doi.org/10.1016/j.lansea.2025.100592>
76. Neighbors CE, Myers ER, Weerasinghe NP, Wijayarathne GB, Bodinayake CK, Nagahawatte A, et al. Influenza Vaccination Implementation in Sri Lanka: A Cost-Effectiveness Analysis. *Vaccines (Basel)*. 2023 May 1 [cited 2025 Aug 3];11(5):932. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC10220975/>
77. WHO Immunization Data portal - South-East Asia Region. 2023 May 3 [cited 2025 Aug 3]; 11(5):932. Doi: <https://doi.org/10.3390/vaccines11050932>
78. Shaheen N, Ngoma C, Adebisi YA, Glover M. Lady health workers smoking cessation initiative in rural Pakistan. *Discover Global Society*. 2024 Dec 1 [cited 2025 Aug 3];2(1):1–7. Doi: <https://doi.org/10.1007/s44282-024-00121-0>
79. Malik MN, Awan MS, Saleem T. Social mobilization campaign to tackle immunization hesitancy in Sargodha and Khushab districts of Pakistan. *J Glob Health*. 2020 [cited 2025 Aug 4];10(2):021302. Doi: <https://doi.org/10.7189/jogh.10.021302>
80. Abdullah M, Ahmad T, Kazmi T, Sultan F, Afzal S, Safdar RM, et al. Community engagement to increase vaccine uptake: Quasi-experimental evidence from Islamabad and Rawalpindi, Pakistan. *PLoS One*. 2022 Dec 1 [cited 2025 Aug 4];17(12):e0274718. Doi: <https://doi.org/10.1371/journal.pone.0274718>
81. Ghia CJ, Rambhad GS. Developing Adult Vaccination Ecosystem in India: Current Perspective and the Way Forward. *Health Serv Res Manag Epidemiol*. 2021;8. Doi: <https://doi.org/10.1177/23333928211030791>
82. Al-Kahtani NK, Aljabri D, Alrawiai S, Alsubaie S, Alasmari M, Aldukhi Z, et al. Factors Affecting Utilization of the E-Health “Seha” Interactive Application for Online Medical Consultation in Saudi Arabia. *Risk Manag Healthc Policy*. 2022 [cited 2025 Aug 4];15:1607–1619. Doi: <https://doi.org/10.2147/RMHP.S349548>
83. Zhang S, Incardona B, Qazi SA, Stenberg K, Campbell H, Nair H, et al. Cost-effectiveness analysis of revised WHO guidelines for management of childhood pneumonia in 74 Countdown countries. *J Glob Health*. 2017 Mar 7 [cited 2025 Aug 4];7(1):01040. Doi: <https://doi.org/10.7189/jogh.07.010409>
84. National Health Vision Pakistan 2016–2025. [cited 2025 Aug 4]. Available from: [https://extranet.who.int/countryplanningcycles/sites/default/files/planning\\_cycle\\_repository/pakistan/national\\_health\\_vision\\_2016-25\\_30-08-2016.pdf](https://extranet.who.int/countryplanningcycles/sites/default/files/planning_cycle_repository/pakistan/national_health_vision_2016-25_30-08-2016.pdf)
85. Kakkar M, Walia K, Yong S, Chatterjee P, Sharma A. Antibiotic resistance and its containment in India. *BMJ*. 2017 Sep 5 [cited 2025 Aug 4];358:j2687. Doi: <https://doi.org/10.1136/bmj.j2687>
86. Priyadarshani GA, Dhammika THMA, Wickramaarachchi PD, Nakandala NDCT, Samarasekara PWGDP. Knowledge, Attitudes and Compliance Towards Directly Observed Treatment Short Course Among Pulmonary Tuberculosis Patients Attending the Chest Clinic at The District General Hospital In, Kalutara. *Proceeding of the Open University Research Sessions*. 2021; Available from: [https://ours.ou.ac.lk/wp-content/uploads/2021/10/ID-198\\_KNOWLEDGE-ATTITUDES-AND-COMPLIANCE-TOWARDS-DIRECTLY-OBSERVED-TREATMENT-SHORT-COURSE-AMONG-PULMONARY-TUBERCULOSIS-PATIENTS ATTENDING-THE-CHEST-CLINIC-AT-THE-DISTRICT-GENERAL-HOSPITAL-INKALUTARA.pdf](https://ours.ou.ac.lk/wp-content/uploads/2021/10/ID-198_KNOWLEDGE-ATTITUDES-AND-COMPLIANCE-TOWARDS-DIRECTLY-OBSERVED-TREATMENT-SHORT-COURSE-AMONG-PULMONARY-TUBERCULOSIS-PATIENTS ATTENDING-THE-CHEST-CLINIC-AT-THE-DISTRICT-GENERAL-HOSPITAL-INKALUTARA.pdf)
87. Rahamn AE, Mhajabin S, Dockrell D, Nair H, El Arifeen S, Campbell H. Managing pneumonia through facility-based integrated management of childhood management (IMCI) services: an analysis of the service availability and readiness among public health facilities in Bangladesh. *BMC Health Serv Res*. 2021 Dec 1;21(1):667. Doi:

<https://doi.org/10.1186/s12913-021-06659-y>

- 88.** Irfan M, Mateo I, Mukhitdinovich SF, Alberca K, Hasan SMU, Khan JK, et al. Challenges in the Management of Community-Acquired Pneumonia in Low- Middle Income Countries. *J Pak Med Assoc.* 2023 Aug. 30 [cited 2025 Aug. 6];73(8):S16-S20. Available from: [https://www.jpma.org.pk/index.php/public\\_html/article/view/10841](https://www.jpma.org.pk/index.php/public_html/article/view/10841)
- 89.** WHO Model List of Essential Medicines - 23rd list, 2023. [cited 2025 Aug 4]. Available from: <https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02>
- 90.** Bunthi C, Baggett HC, Gregory CJ, Thamthitawat S, Yingyong T, Paveenkittiporn W, et al. Enhanced surveillance for severe pneumonia, Thailand 2010-2015. *BMC Public Health.* 2019 May 10 [cited 2025 Aug 4];19(3):472. Doi: <https://doi.org/10.1186/s12889-0196774-5>
- 91.** Daka DW, Wordofa MA, Woldie M, Persson LÅ, Berhanu D. Quality of clinical assessment and management of sick children by health extension workers in four regions of Ethiopia: A cross-sectional survey. *PLoS One.* 2020 Sep 1; 15(9):e0239361. Doi: <https://doi.org/10.1371/journal.pone.0239361>
- 92.** Jamatia B, Jena T. Capacity building in HIV/AIDS care in antiretroviral therapy center through open and distance learning. *CHRISMED Journal of Health and Research.* 2018 [cited 2025 Aug 4];5(4):264. Doi: [https://doi.org/10.4103/cjhr.cjhr\\_93\\_18](https://doi.org/10.4103/cjhr.cjhr_93_18)
- 93.** Pfurtscheller T, Lam F, Shah R, Shohel R, Sans MS, Tounaikok N, et al. Predicting the potential impact of scaling up four pneumonia interventions on under-five pneumonia mortality: A prospective Lives Saved Tool (LiST) analysis for Bangladesh, Chad, and Ethiopia. *J Glob Health.* 2024 [cited 2025 Aug 4];14:04001. Doi: <https://doi.org/10.7189/jogh.14.04001>
- 94.** Hashad N, Stewart D, Perumal D, Abdulrazzaq N, Tonna AP. Antimicrobial stewardship programme implementation in the UAE: perspectives of key stakeholders using Consolidated Framework for Implementation Research. *Journal of Hospital Infection.* 2023 Jul 1 [cited 2025 Aug 4];137:69–76. Doi: <https://doi.org/10.1016/j.jhin.2023.05.003>
- 95.** Government of Pakistan. National Digital Health Framework of Pakistan, 2022-2030. National Digital Health Framework. Available from: <https://phkh.nhsr.pak/sites/default/files/2022-06/National%20Digital%20Health%20Framework%20Pakistan%202022-30.pdf>
- 96.** PARTNERS AT THE FRONTLINE -WHO and the Global Fund making impact in countries – Report. 2024 [cited 2025 Aug 4]. Available from: [https://www.theglobalfund.org/media/14794/core\\_2024-results\\_report\\_en.pdf](https://www.theglobalfund.org/media/14794/core_2024-results_report_en.pdf)
- 97.** Haider S, Health MHBG, 2025 undefined. Seasonal influenza surveillance and vaccination policies in the WHO South-East Asian Region. *gh.bmj.com.* 2025 [cited 2025 Aug 4];10(2):e017271. Doi: <https://doi.org/10.1136/bmjgh-2024-017271>
- 98.** Kibongani Volet A, Scavone C, Catalán-Matamoros D, Capuano A. Vaccine Hesitancy Among Religious Groups: Reasons Underlying This Phenomenon and Communication Strategies to Rebuild Trust. *Front Public Health.* 2022 Feb 7;10. Doi: <https://doi.org/10.3389/fpubh.2022.824560>
- 99.** Tran DM, Thanh Dung N, Minh Duc C, Ngoc Hon H, Minh Khoi L, Phuc Hau N, et al. Status of Digital Health Technology Adoption in 5 Vietnamese Hospitals: Cross-Sectional Assessment. *JMIR Form Res.* 2025 Feb 3 [cited 2025 Aug 4];9(1):e53483. Doi: <https://doi.org/10.2196/53483>
- 100.** Alnajjar MS, Alnsour L, Saeed D, Kurdi HB, Bsoul S, Aburuz S, et al. The impact of adherence to community-acquired pneumonia (CAP) management guidelines on improving clinical outcomes in hospitalized patients. *Pharm Pract (Granada).* 2023 Sep 27 [cited 2025 Aug 4];21(3):1–7. Available from: <https://www.pharmacypractice.org/index.php/pp/article/view/2844>
- 101.** Khanthavudh C, Grealish A, Tzouvara V, Leamy M. Supporting healthcare in rural communities in Thailand: An exploratory qualitative study to understand the role and current mental health practices of village health volunteers. *PLoS One.* 2025 Mar 1 [cited 2025 Aug 4];20(3):e0320559. Doi: <https://doi.org/10.1371/journal.pone.0320559>

- 102.**Anwar B, Uzair S. Pakistan Clinical Research Landscape Report 2022. A Collaborative Project Of Appna Merit And Bmy Health, Version 1 [cited 2025 Aug 4]; Available from: <https://bmyhealth.com/wp-content/uploads/2024/02/Pakistan-Clinical-ResearchLandscape-Report-for-version1.pdf>
- 103.**Nair S, Gupta ED, Maniram YS, Chandiok K, Ovung S. Indian Council of Medical Research (ICMR) Annual Report 2023-2024. 2024 [cited 2025 Aug 4]. Available from: [https://www.icmr.gov.in/icmrobject/uploads/Documents/1744706555\\_icmr\\_annualreport\\_2023-24\\_78804328\\_1.pdf](https://www.icmr.gov.in/icmrobject/uploads/Documents/1744706555_icmr_annualreport_2023-24_78804328_1.pdf)
- 104.**Communicable Disease Surveillance Program of Sri Lanka - Epidemiology Unit - Ministry of Health - Sri Lanka. 2023 [cited 2025 Aug 4]. Available from: [https://www.epid.gov.lk/storage/post/pdfs/en\\_643fb35101272\\_en\\_641005964d33d\\_Communicable%20Disease%20Surveillance%20-%20Final.pdf](https://www.epid.gov.lk/storage/post/pdfs/en_643fb35101272_en_641005964d33d_Communicable%20Disease%20Surveillance%20-%20Final.pdf)
- 105.**Qamar MU, Rizwan M, Uppal R, Khan AA, Saeed U, Ahmad K, et al. Antimicrobial susceptibility and clinical characteristics of multidrug-resistant polymicrobial infections in Pakistan, a retrospective study 2019–2021. *Future Microbiol.* 2023 Nov 1 [cited 2025 Aug 4];18(17):1265–77. Doi: <https://doi.org/10.2217/fmb-2023-0110>
- 106.**Aslam B, Chaudhry TH, Arshad MI, Muzammil S, Siddique AB, Yasmeen N, et al. Distribution and genetic diversity of multi-drug-resistant *Klebsiella pneumoniae* at the human–animal–environment interface in Pakistan. *Front Microbiol.* 2022 Sep 6 [cited 2025 Aug 4];13:898248. Doi: <https://doi.org/10.3389/fmicb.2022.898248>
- 107.**Akhter S, Rizvi N, Bhura S, Warraich UA. Management of community acquired pneumonia by family physicians. *Pak J Med Sci.* 2017 Jul 1 [cited 2025 Aug 4];33(4):783–7. Doi: <https://doi.org/10.12669/pjms.334.12577>
- 108.**Abid I, Qureshi N, ... NLCJ of, 2024 undefined. Point-of-care lung ultrasound in detecting pneumonia: A systematic review. *pmc.ncbi.nlm.nih.gov.* [cited 2025 Aug 4]; 60:37–48. Doi: <https://doi.org/10.29390/001c.92182>
- 109.**Setiawan E, Abdul-Aziz MH, Roberts JA, Cotta MO. Hospital-Based Antimicrobial Stewardship Programs Used in Low-and Middle-Income Countries: A Scoping Review. *Microbial Drug Resistance.* 2022 May 1 [cited 2025 Aug 4];28(5):566–84. Doi: <https://doi.org/10.1089/mdr.2021.0363>
- 110.**Ajulo S, Awosile B. Global antimicrobial resistance and surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across participating countries. *PLoS One.* 2024 Feb 1;19(2):e0297921. Doi: <https://doi.org/10.1371/journal.pone.0297921>
- 111.**Antimicrobial resistance SEARO. 2023. [cited 2025 Aug 4]. Available from: <https://www.who.int/southeastasia/health-topics/antimicrobial-resistance>
- 112.**Fadhil I, Ali R, Al-Raisi SS, Belaila BA Bin, Galadari S, Javed A, et al. Review of National Healthcare Systems in the Gulf Cooperation Council Countries for Noncommunicable Diseases Management. *Oman Med J.* 2022 May 1 [cited 2025 Aug 4];37(3):e370. Doi: <https://doi.org/10.5001/omj.2021.96>
- 113.**Kim TJ, Lee KH, Choe YH, Lee KS. Pulmonary Infection (Pneumonia). In: *Emergency Chest Radiology.* Springer, Singapore; 2021 [cited 2025 Aug 4]. p. 119–41. Doi: [https://doi.org/10.1007/978-981-33-4396-2\\_8](https://doi.org/10.1007/978-981-33-4396-2_8)
- 114.**Eshwara VK, Mukhopadhyay C, Rello J. Community-acquired bacterial pneumonia in adults: An update. *Indian Journal of Medical Research.* 2020 Apr 1 [cited 2025 Aug 4];151(4):287–302. Doi: [https://doi.org/10.4103/ijmr.ijmr\\_1678\\_19](https://doi.org/10.4103/ijmr.ijmr_1678_19)
- 115.**Olson G, Davis AM. Diagnosis and Treatment of Adults with Community-Acquired Pneumonia. *JAMA.* 2020 Mar 3 [cited 2025 Aug 4];323(9):885–6. Doi: <https://doi.org/10.1001/jama.2019.21118>
- 116.**Xu LY, Wang CC, Peng XX, Jiao Y, Zhao CZ, Zhang L, et al. Empirical antibiotic treatment strategies for community-acquired pneumonia: a network meta-analysis. *J Glob Antimicrob Resist.* 2022 Sep 1 [cited 2025 Aug 4];30:1–9. Doi: <https://doi.org/10.1016/j.jgar.2022.05.009>
- 117.**Montes-Andujar L, Tinoco E, Baez-Pravia O, Martin-Saborido C, Blanco-Schweizer P, Segura C, et al. Empiric antibiotics for community-acquired pneumonia in adult patients: a

- systematic review and a network meta-analysis. *Thorax*. 2021 Oct 1 [cited 2025 Aug 4];76(10):1020–31. Doi: <https://doi.org/10.1136/thoraxjnl-2019-214054>
- 118.** Brar NK, Niederman MS. Management of community-acquired pneumonia: a review and update. *Ther Adv Respir Dis*. 2011 Feb [cited 2025 Aug 4];5(1):61–78. Doi: <https://doi.org/10.1177/1753465810381518>
- 119.** Redondo E, Rivero-Calle I, Mascarós E, Ocaña D, Jimeno I, Gil Á, et al. Vaccination against Community-Acquired Pneumonia in Spanish Adults: Practical Recommendations by the NeumoExperts Prevention Group. *Antibiotics* 2023, Vol 12, Page 138. 2023 Jan 10 [cited 2025 Aug 4];12(1):138. Doi: <https://doi.org/10.3390/antibiotics12010138>
- 120.** Tanzella G, Motos A, Battaglini D, Meli A, Torres A. Optimal approaches to preventing severe community-acquired pneumonia. *Expert Rev Respir Med*. 2019 Oct [cited 2025 Aug 4];13(10):1005–18. Doi: <https://doi.org/10.1080/17476348.2019.1656531>
- 121.** Sheth HS, Grimes VD, Rudge D, Ayers B, Moreland LW, Fischer GS, et al. Improving Pneumococcal Vaccination Rates in Rheumatology Patients by Using Best Practice Alerts in the Electronic Health Records. *J Rheumatol*. 2021 Sep 1 [cited 2025 Aug 4];48(9):1472–9. Available from: <https://www.jrheum.org/content/48/9/1472>
- 122.** Guideline for Electronic Medical Record Transition in Healthcare Facilities, Health Informatics and Smart health Department, Dubai Health Authority, Government of Dubai. 2024 [cited 2025 Aug 4]. Available from: <https://www.dha.gov.ae/uploads/072024/EMR%20Transition%20Guideline2024727664.pdf>
- 123.** Continuing Medical Education - College of Physicians and Surgeons Pakistan. [cited 2025 Aug 4]. Available from: <https://www.cpsp.edu.pk/cme.php>
- 124.** Ferranti M, Degnan K, Do D, Hamilton KW, Dutcher L. Validation of an Electronic Dashboard in Identifying Excess Duration of Antibiotics for Pneumonia. *Open Forum Infect Dis*. 2023 Nov 27 [cited 2025 Aug 4];10(Suppl 2):ofad500.1032. Doi: <https://doi.org/10.1093/ofid/ofad500.1032>
- 125.** Zehra SR, Khan SM, Mehmood S, Farooqi J, Jabeen K. Isolation and Epidemiology of Respiratory Bacteria from Unusual Sites: Demographic, Seasonal, and Geographic Distribution in a Laboratory-Based Study from a Tertiary Care Hospital in Karachi, Pakistan. *Cureus*. 2025 Mar 7 [cited 2025 Aug 4];17(3):e80213. Doi: <https://doi.org/10.7759/cureus.80213>
- 126.** Zafar A, Hasan R, Nizamuddin S, Mahmood N, Mukhtar S, Ali F, et al. Antibiotic susceptibility in *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Streptococcus pyogenes* in Pakistan: A review of results from the survey of antibiotic resistance (SOAR) 2002–15. *Journal of Antimicrobial Chemotherapy*. 2016 May 1;71 Suppl 1:i103–9. Doi: <https://doi.org/10.1093/jac/dkw076>
- 127.** Palmborg A, Skovdal M, Molden T, Åhman H, Chen L, Banefelt J. Invasive pneumococcal disease among the elderly in the later era of paediatric pneumococcal conjugate vaccination—A longitudinal study over 10 years based on public surveillance data in the Nordics. *PLoS One*. 2023 Jun 1 [cited 2025 Aug 4];18(6):e0287378. Doi: <https://doi.org/10.1371/journal.pone.0287378>
- 128.** WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), Pakistan. 2024 [cited 2025 Aug 4]. 2024. Available from: <https://www.unicef.org/pakistan/media/6001/file/WUENIC%20Pakistan%202023.pdf.pdf>
- 129.** Ghia CJ, Horn EK, Rambhad G, Perdrizet J, Chitale R, Wasserman MD. Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India. *Infect Dis Ther*. 2021 Dec 1 [cited 2025 Aug 4];10(4):2271–88. Doi: <https://doi.org/10.1007/s40121-021-00498-4>
- 130.** ACIP Recommendations | ACIP | CDC. 2025 [cited 2025 Aug 4]. Available from: <https://www.cdc.gov/acip/vaccine-recommendations/index.html>
- 131.** Binsuwaidan R, Alghamdi EM, Otaif EA, ALqutaym MS, Mohzari YA, Alrashed AA, et al. Cross-sectional investigation of pneumococcal vaccination patterns in HIV patients at a tertiary care hospital in Riyadh, Saudi Arabia. *J Infect Public Health*. 2025 Jul 1 [cited 2025 Aug

4];18(7):102783. Doi: <https://doi.org/10.1016/j.jiph.2025.102783>

**132.** Barqawi HJ, Samara KA, Hassan MS, Amawi FB. Adult Vaccination in the United Arab Emirates—A Physicians' Knowledge and Knowledge Sources Study. *Front Public Health*. 2022 Apr 14 [cited 2025 Aug 4];10:865759. Doi: <https://doi.org/10.3389/fpubh.2022.865759>

**133.** Ministry of Health and Prevention - UAE. [cited 2025 Aug 4]. Available from: <https://mohap.gov.ae/en/home>

**134.** Kanwal K, Asif M, Khalid SG, Liu H, Qurashi AG, Abdullah S. Current Diagnostic Techniques for Pneumonia: A Scoping Review. *Sensors (Basel)*. 2024 Jul 1 [cited 2025 Aug 4];24(13):4291. Doi: <https://doi.org/10.3390/s24134291>

**135.** Chalmers JD. The Modern Diagnostic Approach to Community-Acquired Pneumonia in Adults. *Semin Respir Crit Care Med*. 2016 Dec 1 [cited 2025 Aug 4];37(6):876–85. Doi: <https://doi.org/10.1055/s-0036-1592125>

**136.** Karacaer C, Karabay O, Gunduz Y, Yaylacı S, Guclu E. Correlation of lung ultrasound and computed tomography findings in COVID-19 pneumonia. *Journal of the College of Physicians and Surgeons Pakistan*. 2021;30(10):S147–52. Doi: <https://doi.org/10.29271/jcpsp.2020.supp2.s147>

**137.** Bitar ZI, Maadarani OS, El-Shably AAM, Al-Ajmi MJ. Diagnostic accuracy of chest ultrasound in patients with pneumonia in the intensive care unit: A single-hospital study. *Health Sci Rep*. 2018 Jan 1 [cited 2025 Aug 4];2(1):e102. Doi: <https://doi.org/10.1002/hsr2.102>

**138.** Desai D, Shah AB, Dela JRC, Mugibel TA, Sumaily KM, Sabi EM, et al. Lung Ultrasonography Accuracy for Diagnosis of Adult Pneumonia: Systematic Review and Meta-Analysis. *Adv Respir Med*. 2024 Jun 1 [cited 2025 Aug 4];92(3):241–53. Doi: <https://doi.org/10.3390/arm92030024>

**139.** Dhawan J, Singh G. Bedside Lung Ultrasound as an Independent Tool to Diagnose Pneumonia in Comparison to Chest X-ray: An Observational Prospective Study from Intensive Care Units. *Indian J Crit Care Med*. 2022 Aug 1 [cited 2025 Aug 4];26(8):920–929. Doi: <https://doi.org/10.5005/jp-journals-10071-24283>

**140.** Khan R, Siddique S, Jabeen F, Rehman A ur, Javed F, Qamber JH. Role of chest X-ray and Lung Ultrasound in diagnosis and treatment of Children and Infants with Pneumonia. *Pakistan Journal of Chest Medicine*. 2021;27(4):352–263. Available from: <https://www.pjcm.net/index.php/pjcm/article/view/854>

**141.** Valley TS, Sjoding MW, Ryan AM, Iwashyna TJ, Cooke CR. Association of Intensive Care Unit Admission with Mortality Among Older Patients with Pneumonia. *JAMA*. 2015 Sep 22 [cited 2025 Aug 4];314(12):1272–9. Doi: <https://doi.org/10.1001/jama.2015.11068>

**142.** Chalfin DB, Trzeciak S, Likourezos A, Baumann BM, Dellinger RP. Impact of delayed transfer of critically ill patients from the emergency department to the intensive care unit. *Crit Care Med*. 2007 22 [cited 2025 Aug 4];35(6):1477–83. Doi: <https://doi.org/10.1097/01.ccm.0000266585.74905.5a>

**143.** Nadarajah T, Dharmalingam L, Galhena HT, Rangana RLP, Perera N, Priyankara WDD. Predictors of mortality in severe community acquired pneumonia in an intensive care unit of Sri Lanka. *Journal of the Ceylon College of Physicians*. 2024 Dec 2022 [cited 2025 Aug 4];55(2):99–106. Doi: <http://dx.doi.org/10.4038/jccp.v55i2.8061>

**144.** Jabeen F, Mishra A, Mateen S, Maharaj A, Kapoor R, Abbas SF, et al. Pneumonia in Geriatric Patients and Prediction of Mortality Based on the Pneumonia Severity Index (PSI), CURB-65, Frailty Index (FI), and FI-Lab21 Scores. *Cureus*. 2024 Jun 5 [cited 2025 Aug 4]16(6):e61719. Doi: <https://doi.org/10.7759/cureus.61719>

**145.** Grossman RF, Ambrusz ME, Fisher AC, Khashab MM, Kahn JB. Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: A post hoc analysis of data from severely ill patients. *Clin Ther*. 2006 Aug 1 [cited 2025 Aug 4];28(8):1175–80. Doi: <https://doi.org/10.1016/j.clinthera.2006.08.013>

**146.** Fleming VH, Xu J, Chen X, Hall D, Southwood RL. Risk of Tendinopathy in Patients Treated with Fluoroquinolone (FQ) Versus Non-Fluoroquinolone Antibiotics for Community-

- Acquired Pneumonia (CAP). *Annals of Pharmacotherapy*. 2024 Aug 1 [cited 2025 Aug 4];58(8):771–80. Doi: <https://doi.org/10.1177/10600280231210275>
- 147.** Postma DF, Spitoni C, Van Werkhoven CH, Van Elden LJR, Oosterheert JJ, Bonten MJM. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: Post-hoc analysis of a cluster-randomized trial. *BMC Infect Dis*. 2019 Jan 7 [cited 2025 Aug 4];19(1):1–12. Doi: <https://doi.org/10.1186/s12879-018-3630-7>
- 148.** Baysultanova RE, Rachina SA, Kotidis IM, Kupriushina OA, Alhalaseh SAK. Management of community-acquired pneumonia in adults with type 2 diabetes mellitus in a multidisciplinary hospital. *PULMONOLOGIYA*. 2022 [cited 2025 Aug 4];32(4):568–75. Doi: <http://dx.doi.org/10.18093/0869-0189-2022-32-4-568-575>
- 149.** Blasi F, Ostermann H, Racketta J, Medina J, McBride K, Garau J. Early versus later response to treatment in patients with community-acquired pneumonia: analysis of the REACH study. *Respir Res*. 2014 Jan 22 [cited 2025 Aug 4];15(1):6. Doi: <https://doi.org/10.1186/14659921-15-6>
- 150.** Cheng AC, Buising KL. Delayed Administration of Antibiotics and Mortality in Patients with Community-Acquired Pneumonia. *Ann Emerg Med*. 2009 May 1 [cited 2025 Aug 4];53(5):618–24. Doi: <https://doi.org/10.1016/j.annemergmed.2008.07.017>
- 151.** Ciarkowski CE, Timbrook TT, Kukhareva PV., Edholm KM, Hatton ND, Hopkins CL, et al. A Pathway for Community-Acquired Pneumonia with Rapid Conversion to Oral Therapy Improves Health Care Value. *Open Forum Infect Dis*. 2020 Nov 1 [cited 2025 Aug 4];7(11). Doi: <https://doi.org/10.1093/ofid/ofaa497>
- 152.** Deshpande A, Klompas M, Guo N, Imrey PB, Pallotta AM, Higgins T, et al. Intravenous to Oral Antibiotic Switch Therapy Among Patients Hospitalized with Community-Acquired Pneumonia. *Clinical Infectious Diseases*. 2023 Jul 26 [cited 2025 Aug 4];77(2):174–85. Doi: <https://doi.org/10.1093/cid/ciad196>
- 153.** Shakeel S, Iffat W, Qamar A, Ghuman F, Yamin R, Ahmad N, et al. Pediatricians' Compliance to the Clinical Management Guidelines for Community-Acquired Pneumonia in Infants and Young Children in Pakistan. *Healthcare* 2021, Vol 9, Page 701. 2021 Jun 9 [cited 2025 Aug 4];9(6):701. Doi: <https://doi.org/10.3390/healthcare9060701>
- 154.** Shumilak G, Sligl WI. Moving Past the Routine Use of Macrolides—Reviewing the Role of Combination Therapy in Community-Acquired Pneumonia. *Curr Infect Dis Rep*. 2018 Nov 1 [cited 2025 Aug 5];20(11):45. Doi: <https://doi.org/10.1007/s11908-018-0651-8>
- 155.** Vikhe VB, Faruqi AA, Patil RS, Patel H, Khandol D, Reddy A. A Study on the Etiology and Clinical Manifestations of Community-Acquired Pneumonia in Adults in Western India. *Cureus*. 2024 Jun 25 [cited 2025 Aug 5];16(6):e63132. Doi: <https://doi.org/10.7759/cureus.63132>
- 156.** Kausar MA, Paul S, Nasir M, Rahman MH, Hoque SMK, Nazir N. Community Acquired Pneumonia in Bangladesh: Sensitivity Pattern, Clinical Courses and Outcome of a CrossSectional Population. *Asian Journal of Medicine and Health*. 2022 Jun 29 [cited 2025 Aug 5];31–40. Doi: <https://doi.org/10.9734/ajmah/2022/v20i1030503>
- 157.** Zhydkov A, Christ-Crain M, Thomann R, Hoess C, Henzen C, Zimmerli W, et al. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia. *Clin Chem Lab Med*. 2015 Mar 1 [cited 2025 Aug 5];53(4):559–66. Doi: <https://doi.org/10.1515/cclm-20140456>
- 158.** Pneumonia in adults: diagnosis and management - Clinical Guideline - CG191 NICE. National Institute of Health and Care Excellence. 2023 [cited 2025 Aug 5]. Available from: <https://www.nice.org.uk/guidance/cg191>
- 159.** Maryam S, Saleem Z, Haseeb A, Usman Qamar M, Amir A, Almarzoky Abuhussain SS, et al. Progress on the Global Research Agenda for Antimicrobial Resistance in Human Health in Pakistan: Findings and Implications. *Infect Drug Resist*. 2025 Jul [cited 2025 Aug 5];18:3795–828. Doi: <https://doi.org/10.2147/idr.s531874>
- 160.** Lan SH, Lai CC, Chang SP, Lu LC, Hung SH, Lin WT. Five-day antibiotic treatment for community-acquired bacterial pneumonia: A systematic review and meta-analysis of

- randomized controlled trials. *J Glob Antimicrob Resist*. 2020 Dec 1 [cited 2025 Aug 5];23:94–9. Doi: <https://doi.org/10.1016/j.jgar.2020.08.005>
- 161.** Iqbal N, Irfan M, Zubairi ABS, Awan S, Khan JA. Association of hypercapnia on admission with increased length of hospital stay and severity in patients admitted with community-acquired pneumonia: a prospective observational study from Pakistan. *BMJ Open*. 2017 Jun 1 [cited 2025 Aug 5];7(6):e013924. Doi: <https://doi.org/10.1136/bmjopen-2016-013924>
- 162.** Gupta D, Agarwal R, Aggarwal A, Singh N, Mishra N, Khilnani G, et al. Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations. *Lung India*. 2012 [cited 2025 Aug 5];29(SUPPL.2):S27–S62. Doi: <https://doi.org/10.4103/0970-2113.99248>
- 163.** Harris AM, Bramley AM, Jain S, Arnold SR, Ampofo K, Self WH, et al. Influence of Antibiotics on the Detection of Bacteria by Culture-Based and Culture-Independent Diagnostic Tests in Patients Hospitalized with Community-Acquired Pneumonia. *Open Forum Infect Dis*. 2017 Nov 1 [cited 2025 Aug 5];4(1):ofx014. Doi: <https://doi.org/10.1093/ofid/ofx014>
- 164.** Giuliano C, Patel CR, Kale-Pradhan PB. A Guide to Bacterial Culture Identification and Results Interpretation. *Pharmacy and Therapeutics*. 2019 Apr 1 [cited 2025 Aug 5];44(4):192–200. PMID: 30930604; PMCID: PMC6428495. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6428495/>
- 165.** Almirall J, Bolibar I, Serra-Prat M, Palomera E, Roig J, Hospital I, et al. Relationship between the Use of Inhaled Steroids for Chronic Respiratory Diseases and Early Outcomes in Community-Acquired Pneumonia. *PLoS One*. 2013 Sep 5 [cited 2025 Aug 5];8(9):e73271. Doi: <https://doi.org/10.1371/journal.pone.0073271>
- 166.** Siemieniuk RAC, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: A systematic review and meta-analysis. *Ann Intern Med*. 2015 Oct 6 [cited 2025 Aug 5];163(7):519–28. Doi: <https://doi.org/10.7326/m15-0715>
- 167.** Iqbal N, Irfan M, Siddiqui F, Arshad V, Zuabairi ABS. Effects of systemic steroids on patients with community-acquired pneumonia: Observational study from a tertiary care hospital of a developing country. *Respir Investig*. 2020 Nov 1 [cited 2025 Aug 5];58(6):495–501. Doi: <https://doi.org/10.1016/j.resinv.2020.05.004>
- 168.** Masuduzzaman SM, Sayedul Islam M, Khairul Anam M, Shahinur Hossain S, Yeasmin D, Shkhawaath Hossain M, et al. Comparative Study of CURB-65, Expanded CURB- 65, PSI and SMART-COP Scoring in the Severity Assessment of Community Acquired Pneumonia. *Chest & Heart Journal*. 2020 [cited 2025 Aug 5];44(2):73–81. Available from: <https://www.banglajol.info/index.php/CHJ/article/view/56974>
- 169.** World Health Organization. Regional Office for South-East Asia. (2010). Guidelines for preventive and social medicine/community medicine/community health curriculum in undergraduate medical education. WHO Regional Office for South-East Asia. [cited 2025 Aug 5]. Available from: <https://iris.who.int/handle/10665/205167>
- 170.** Chauhan A, Majmundar A, Lakhani S, Lakhani J. A comparative study between CURB-65 and PSI/PORT score as predictors for icu admission and mortality in community acquired pneumonia patients. *Indian Journal of Clinical Anaesthesia*. 2024 [cited 2025 Aug 5];11(2):181–7. Doi: <http://dx.doi.org/10.18231/j.ijca.2024.036>
- 171.** Markussen DL, Wathne JS, Ritz C, van Werkhoven CH, Serigstad S, Bjørneklett RO, et al. Determinants of non-adherence to antibiotic treatment guidelines in hospitalized adults with suspected community-acquired pneumonia: a prospective study. *Antimicrob Resist Infect Control*. 2024 Dec 1 [cited 2025 Aug 5];13(1):1–18. Doi: <https://doi.org/10.1186/s13756-024-01494-2>
- 172.** Fésüs A, Benkő R, Matuz M, Engi Z, Ruzsa R, Hambalek H, et al. Impact of Guideline Adherence on Outcomes in Patients Hospitalized with Community-Acquired Pneumonia (CAP) in Hungary: A Retrospective Observational Study. *Antibiotics* 2022, Vol 11, Page 468. 2022 Mar 30 [cited 2025 Aug 5];11(4):468. Doi: <https://doi.org/10.3390/antibiotics11040468>

- 173.**Zoysa WD, Palangasinghe D, Bodinayake C, Nagahawatte A, Gamage J, Iglesias-Ussel MD, et al. Electronic Clinical Decision Support Tools to Manage Patients with Lower Respiratory Tract Infection: Clinicians' Perspectives in Sri Lanka. *American Journal of Tropical Medicine and Hygiene*. 2025 [cited 2025 Aug 5];112(5):1168–74. Doi: <https://doi.org/10.4269/ajtmh.24-0576>
- 174.**Mahboub B, Al Zaabi A, Al Ali OM, Ahmed R, Niederman MS, El-Bishbishi R. Real life management of community-acquired Pneumonia in adults in the Gulf region and comparison with practice guidelines: A prospective study. *BMC Pulm Med*. 2015 Sep 30 [cited 2025 Aug 5];15(1):1–9. Doi: <https://doi.org/10.1186/s12890-015-0108-x>
- 175.**Shannon KL, Osula VO, Shaw-Saliba K, Hardick J, McBryde B, Dugas A, et al. Viral coinfections are associated with increased rates of hospitalization in those with influenza. *Influenza Other Respir Viruses*. 2022 Jul 1 [cited 2025 Aug 5];16(4):780–8. Doi: <https://doi.org/10.1111/irv.12967>
- 176.**Badar N, Salman M, Nisar N, Mirza HA, Ahad A, Ahmad F, et al. Unraveling influenza sentinel surveillance in Pakistan 2008–2024: Epidemiological insights during the pre and post pandemic period of COVID-19. *J Infect Public Health*. 2024 Dec 1 [cited 2025 Aug 5];17(12). Doi: <https://doi.org/10.1016/j.jiph.2024.102595>
- 177.**Hussain M, Nasir N, Irfan M, Hasan Z. Clinical characteristics and outcomes of patients with H1N1 influenza pneumonia admitted at a tertiary care hospital in Karachi, Pakistan. *Pneumonia* 2020 12:1. 2020 Jul 5 [cited 2025 Aug 5];12(1):1–6. Doi: <https://doi.org/10.1186/s41479-020-00070-7>
- 178.**Interim Guidance on the Use of Antiviral Medications for Treatment of Human Infections with Novel Influenza A Viruses Associated with Severe Human Disease | Bird Flu | CDC. 2025 [cited 2025 Aug 5]. Available from: <https://www.cdc.gov/bird-flu/hcp/cliniciansevaluating-patients/interim-guidance-treatment-humans.html>
- 179.**Global Influenza Strategy 2019–2030 - World Health Organization. 2019 [cited 2025 Aug 5]. Available from: <https://www.who.int/publications/i/item/9789241515320>
- 180.**National Antimicrobial Resistance (AMR) Surveillance Report Pakistan 2021–2022. National Institute of Health, Pakistan. 2021. Available from: [www.nih.org.pk](http://www.nih.org.pk)
- 181.**Shen L, Jhund PS, Anand IS, Bhatt AS, Desai AS, Maggioni AP, et al. Incidence and Outcomes of Pneumonia in Patients with Heart Failure. *J Am Coll Cardiol*. 2021 Apr 27 [cited 2025 Aug 5];77(16):1961–73. Doi: <https://doi.org/10.1016/j.jacc.2021.03.001>
- 182.**Sultan N, Miran MS, Mushtaq F, Zahra Z, Haseeb S, Sultan S. Myocardial Infarction Among Hospitalized Patients with Community Acquired Pneumonia: A Retrospective Observational Study. *Pakistan Journal of Physiology*. 2023 Jun 30 [cited 2025 Aug 5];19(2):36–9. Doi: <http://dx.doi.org/10.69656/pjp.v19i2.1518>
- 183.**Horodinschi RN, Bratu OG, Dediu GN, Pantea Stoian A, Motofei I, Diaconu CC. Heart failure and chronic obstructive pulmonary disease: a review. *Acta Cardiol*. 2020 Mar 3 [cited 2025 Aug 5];75(2):97–104. Doi: <https://doi.org/10.1080/00015385.2018.1559485>
- 184.**Riccobono E, Bussini L, Giannella M, Viale P, Rossolini GM. Rapid diagnostic tests in the management of pneumonia. *Expert Rev Mol Diagn*. 2022 Jan 2 [cited 2025 Aug 6];22(1):49–60. Doi: <https://doi.org/10.1080/14737159.2022.2018302>
- 185.**Serigstad S, Ritz C, Faurholt-Jepsen D, Markussen D, Ebbesen MH, Kommedal Ø, et al. Impact of rapid molecular testing on diagnosis, treatment, and management of community-acquired pneumonia in Norway: a pragmatic randomised controlled trial (CAPNOR). *Trials*. 2022 Dec 1 [cited 2025 Aug 6];23(1):622. Doi: <https://doi.org/10.1186/s13063-02206467-7>
- 186.**Irfan M, Farooqi J, Hasan R. Community-acquired pneumonia. *Curr Opin Pulm Med*. 2013 May 1 [cited 2025 Aug 6];19(3):208. Available from: [https://ecommons.aku.edu/pakistan\\_fhs\\_mc\\_med\\_intern\\_med/53](https://ecommons.aku.edu/pakistan_fhs_mc_med_intern_med/53)
- 187.**Mishra M, Shendre P, Gade N, Shete V, Nag S, Dutta SV. Impact of BioFire FilmArray Multiplex PCR in the Detection of Microbial Agents causing Severe Acute Respiratory

Infection in the COVID-19 Era: A Cross-sectional Study from a Tertiary Care Hospital in Central India. *JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH*. 2024;18(1):06–12. Doi: <https://doi.org/10.7860/JCDR/2024/65688.18972>

**188.** Senok A, Dabal L Al, Alfaresi M, Habous M, Celiloglu H, Bashiri S, et al. Clinical Impact of the BIOFIRE Blood Culture Identification 2 Panel in Adult Patients with Bloodstream Infection: A Multicentre Observational Study in the United Arab Emirates. *Diagnostics*. 2023 Jul 1 [cited 2025 Aug 6];13(14):2433. Doi: <https://doi.org/10.3390/diagnostics13142433>

**189.** Debnath AK, Todi SK. Clinical Profile of Patients Admitted with Complicated Respiratory Tract Infection in ICU with Positive Multiplex PCR (Biofire) Panel. *Indian J Crit Care Med*. 2024 Mar 7 [cited 2025 Aug 6];28(Suppl 1):S596–S602. Doi: <https://doi.org/10.5005/jaypee-journals-10071-24667.226>

**190.** Marin-Corral J, Pascual-Guardia S, Amati F, Aliberti S, Masclans JR, Soni N, et al. Aspiration

Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized with Community-Acquired Pneumonia. *Chest*. 2021 Jan 1 [cited 2025 Aug 6];159(1):58–72. Doi: <https://doi.org/10.1016/j.chest.2020.06.079>

**191.** Aliberti S, Dela Cruz CS, Amati F, Sotgiu G, Restrepo MI. Community-acquired pneumonia.

*The Lancet*. 2021 Sep 4 [cited 2025 Aug 6];398(10303):906–19. Doi: [https://doi.org/10.1016/s0140-6736\(21\)00630-9](https://doi.org/10.1016/s0140-6736(21)00630-9)

**192.** Khan A, Ali N, Jan R, Ullah U. Evaluating Modifiable and Non-Modifiable Risk Factors Associated with Mortality in Aspiration Pneumonia | *Pakistan Journal of Chest Medicine*. *Pakistan Journal of Chest Medicine*. 2025 [cited 2025 Aug 6];31(1):24–9. Available from: <https://www.pjcm.net/index.php/pjcm/article/view/1000>

**193.** Khilnani GC, Zirpe K, Hadda V, Mehta Y, Madan K, Kulkarni A, et al. Guidelines for Antibiotic Prescription in Intensive Care Unit. *Indian J Crit Care Med*. 2019 [cited 2025 Aug 6];23(Suppl 1):S1–S63. Doi: <https://doi.org/10.5005/jp-journals-10071-23101>

**194.** Memish ZA, Arabi YM, Ahmed QA, Shibl AM, Niederman MS. Executive summary of the Gulf Cooperation Council practice guidelines for the management of community-acquired pneumonia. *J Chemother*. 2007 [cited 2025 Aug 6];19 Suppl 1:7–11. Doi: <https://doi.org/10.1080/1120009x.2007.11782428>

**195.** Chen Y, Gu W, He B, Gao H, Sun P, Li Q, et al. Impact of a community-based health education intervention on awareness of influenza, pneumonia, and vaccination intention in chronic patients. *Hum Vaccin Immunother*. 2022 Jan 31 [cited 2025 Aug 6];18(1):1–8. Doi: <https://doi.org/10.1080/21645515.2021.1959828>

**196.** Adamuz J, Viasus D, Simonetti A, Jiménez-Martínez E, Molero L, González-Samartino M, et al. Impact of an Educational Program to Reduce Healthcare Resources in Community-Acquired Pneumonia: The EDUCAP Randomized Controlled Trial. *PLoS One*. 2015 Oct 13 [cited 2025 Aug 6];10(10):e0140202. Doi: <https://doi.org/10.1371/journal.pone.0140202>

**197.** Khan A. Evaluating the Effectiveness of Public Health Campaigns on Immunization Rates in Pakistan. *Pakistan Journal of Healthcare Research*. 2024 Jun 30 [cited 2025 Aug 6];1(1):31–7. Available from: <https://pjhr.com.pk/index.php/journal/article/view/5>

**198.** Annual Progress Report 2022, GAVI. The Vaccine Alliance. [cited 2025 Aug 6]. Available from: <https://www.gavi.org/progress-report-2022>

